<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Aging Brain</journal-id><journal-id journal-id-type="iso-abbrev">Aging Brain</journal-id><journal-id journal-id-type="pmc-domain-id">4401</journal-id><journal-id journal-id-type="pmc-domain">agbrain</journal-id><journal-title-group><journal-title>Aging Brain</journal-title></journal-title-group><issn pub-type="epub">2589-9589</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12221426</article-id><article-id pub-id-type="pmcid-ver">PMC12221426.1</article-id><article-id pub-id-type="pmcaid">12221426</article-id><article-id pub-id-type="pmcaiid">12221426</article-id><article-id pub-id-type="pmid">40606490</article-id><article-id pub-id-type="doi">10.1016/j.nbas.2025.100143</article-id><article-id pub-id-type="pii">S2589-9589(25)00009-X</article-id><article-id pub-id-type="publisher-id">100143</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Nigrostriatal dopaminergic neurotransmission and resilience to peripheral systemic risk factors for gait slowing upon transition to uneven surfaces in older adult</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name name-style="western"><surname>Chahine</surname><given-names initials="LM">Lana M.</given-names></name><email>lchahine2018@gmail.com</email><xref rid="af005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au010"><name name-style="western"><surname>Rosso</surname><given-names initials="A">Andrea</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au015"><name name-style="western"><surname>Troidl</surname><given-names initials="I">Ian</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au020"><name name-style="western"><surname>Ganguli</surname><given-names initials="M">Mary</given-names></name><xref rid="af005" ref-type="aff">a</xref><xref rid="af010" ref-type="aff">b</xref><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au025"><name name-style="western"><surname>Newman</surname><given-names initials="A">Anne</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au030"><name name-style="western"><surname>Cummings</surname><given-names initials="S">Steven</given-names></name><xref rid="af020" ref-type="aff">d</xref><xref rid="af025" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au035"><name name-style="western"><surname>Studenski</surname><given-names initials="S">Stephanie</given-names></name><xref rid="af030" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au040"><name name-style="western"><surname>Lopresti</surname><given-names initials="B">Brian</given-names></name><xref rid="af035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au045"><name name-style="western"><surname>Royse</surname><given-names initials="S">Sarah</given-names></name><xref rid="af035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au050"><name name-style="western"><surname>Huppert</surname><given-names initials="T">Theodore</given-names></name><xref rid="af040" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au055"><name name-style="western"><surname>Redfern</surname><given-names initials="M">Mark</given-names></name><xref rid="af045" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au060"><name name-style="western"><surname>Sparto</surname><given-names initials="PJ">Patrick J.</given-names></name><xref rid="af050" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au065"><name name-style="western"><surname>Bohnen</surname><given-names initials="NI">Nico I.</given-names></name><xref rid="af055" ref-type="aff">k</xref><xref rid="af060" ref-type="aff">l</xref></contrib><contrib contrib-type="author" id="au070"><name name-style="western"><surname>Rosano</surname><given-names initials="C">Caterina</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><aff id="af005"><label>a</label>Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA</aff><aff id="af010"><label>b</label>Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA</aff><aff id="af015"><label>c</label>Departments of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA</aff><aff id="af020"><label>d</label>San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA, USA</aff><aff id="af025"><label>e</label>Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA</aff><aff id="af030"><label>f</label>Division of Geriatric Medicine, University of Pittsburgh School of Medicine, PA, USA</aff><aff id="af035"><label>g</label>Department of Radiology, University of Pittsburgh, USA</aff><aff id="af040"><label>h</label>Department of Electrical and Computer Engineering, University of Pittsburgh, Pittsburgh, USA</aff><aff id="af045"><label>i</label>Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, USA</aff><aff id="af050"><label>j</label>Department of Physical Therapy, School of Health and Rehabilitation Sciences, University of Pittsburgh, USA</aff><aff id="af055"><label>k</label>Department of Radiology, University of Michigan, Ann Arbor, MI, USA</aff><aff id="af060"><label>l</label>Departments of Neurology &amp; Radiology, School of Medicine, University of Michigan, Ann Arbor, MI, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author at: 3471 Fifth Avenue, Kaufmann Medical Building, Suite 811, Pittsburgh, PA 15213, USA. <email>lchahine2018@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>20</day><month>6</month><year>2025</year></pub-date><volume>8</volume><issue-id pub-id-type="pmc-issue-id">491466</issue-id><elocation-id>100143</elocation-id><history><date date-type="received"><day>28</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>2</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-03 22:25:49.373"><day>03</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="ab005"><p>Identifying mechanisms that compensate for slow gait speed in older adults is crucial. Dopaminergic neurotransmission curbs deleterious associations of cerebrovascular disease with gait, but whether it compensates for peripheral systemic risk factors (PSRF) for gait slowing has not been studied. In this cross-sectional study of community-dwelling older adults, we examined the relationship between nigrostriatal dopaminergic terminal integrity and gait speed in individuals with and without&#160;&#8805;&#160;1 PSRF for gait slowing: obesity, joint pain, or reduced muscle strength. The primary outcome was gait speed cost (%GSC) on transition from even to uneven surface. Participants underwent dopaminergic imaging with dihydrotetrabenazine [<sup>11</sup>C]DTBZ positron emission tomography. Among 197 individuals, (mean (SD) age 74.92 (4.53) years; 61.93&#160;% female; 90.86&#160;% White), 130 (65.99&#160;%) had&#160;&#8805;&#160;1 PSRF. Relationship between posterior putamen [<sup>11</sup>C]DTBZ binding and %GSC was modified by PSRF; in those with&#160;&#8805;&#160;1 PSRF (but not in those with no PSRF), posterior putamen [<sup>11</sup>C]DTBZ binding was associated with %GSC (&#946;&#160;=&#160;0.198, p&#160;=&#160;0.03) independent of potential confounders. This cross-sectional study indicates that higher striatal dopaminergic neurotransmission may compensate for the effects of PSRF on gait slowing.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Dopamine</kwd><kwd>Gait slowing</kwd><kwd>Resilience</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><def-list><title>Abbreviations</title><def-item><term id="k0025">MYHAT</term><def><p>Monongahela-Youghiogheny Healthy Aging Team study</p></def></def-item><def-item><term id="k0035">PET</term><def><p>Positron Emission Tomography</p></def></def-item><def-item><term id="k0045">PSRF</term><def><p>Peripheral Systemic Risk Factors</p></def></def-item><def-item><term id="k0055">SOMMA</term><def><p>Study of Muscle, Mobility and Aging</p></def></def-item><def-item><term id="k0065">VMAT2</term><def><p>type-2 vesicular monoamine transporter</p></def></def-item></def-list></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0005">With increasing age, gait becomes slower and less automated, requiring more attentional resources [<xref rid="b0005" ref-type="bibr">1</xref>,<xref rid="b0010" ref-type="bibr">2</xref>]. These changes in gait have consequences such as increased risk of falls, disability [<xref rid="b0015" ref-type="bibr">3</xref>], and premature mortality [<xref rid="b0020" ref-type="bibr">4</xref>]. The cause of gait slowing in older adults is multifactorial. It can be due to peripheral systemic factors including joint pain, obesity, and reduced muscle strength, among others [<xref rid="b0025" ref-type="bibr">[5]</xref>, <xref rid="b0030" ref-type="bibr">[6]</xref>, <xref rid="b0035" ref-type="bibr">[7]</xref>, <xref rid="b0040" ref-type="bibr">[8]</xref>, <xref rid="b0045" ref-type="bibr">[9]</xref>]. In addition, central nervous system factors, including cerebral small vessel disease, contribute to gait slowing in older adults without diagnosed neurologic disorders [<xref rid="b0010" ref-type="bibr">2</xref>,<xref rid="b0050" ref-type="bibr">10</xref>].</p><p id="p0010">Some older adults maintain mobility and do not exhibit substantial gait slowing despite having one or more risk factors for gait slowing. Indeed, we have demonstrated that&#160;&#8764;&#160;20&#160;% of older adults maintain fast walking speed even in the presence of cerebral small vessel disease and peripheral systemic risk factors (PSRF). These individuals may be demonstrating resilience: the maintenance of normal walking speed despite risk factors for slower gait [<xref rid="b0055" ref-type="bibr">11</xref>,<xref rid="b0060" ref-type="bibr">12</xref>]. Like gait slowing, resilience is likely also multifactorial. Hypothetically, resilience could result from either normal or supra-normal function in some components that affect gait, which compensate for abnormal function in other components. We posit that dopaminergic neurotransmission is a candidate pathway that offers compensation to the detrimental effects of PSRF on gait speed The nigrostriatal dopaminergic system plays a critical role in motor control; nigrostriatal dopaminergic neurotransmission regulates the automated execution of overlearned motor tasks via its connections with sensorimotor cortical and subcortical areas [<xref rid="b0065" ref-type="bibr">13</xref>] and dopaminergic neurotransmission positively predicts walking speed [<xref rid="b0070" ref-type="bibr">14</xref>].</p><p id="p0015">We previously found that the genotype in a dopamine-metabolism gene that is associated with higher synaptic dopamine levels (Met/Met catechol-o-methyltransferase) attenuates the negative effects of age-related cerebral small vessel disease on gait speed [<xref rid="b0075" ref-type="bibr">15</xref>]. These findings are consistent with post-mortem evidence that a combination of nigral dopamine neurons loss and cerebral small vessel disease best predict walking impairment in older adults [<xref rid="b0080" ref-type="bibr">[16]</xref>, <xref rid="b0085" ref-type="bibr">[17]</xref>, <xref rid="b0090" ref-type="bibr">[18]</xref>]. Less is known about the contributions of dopaminergic neurotransmission to compensation for deleterious effects of PSRF on gait slowing. Importantly, dopaminergic neurotransmission is potentially modifiable pharmacologically, thereby offering novel approaches to treat non-resilient older adults in a targeted fashion.</p><p id="p0020">Our objectives were to examine among community dwelling older adults with and without PSRF for gait slowing the relationship between nigrostriatal dopaminergic terminal integrity and gait speed cost (%GSC) when walking on an uneven vs even surface. We selected %GSC as our primary outcome as this complex task can reflect changes in walking speed resulting from real-world perturbations [<xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>], and may be more sensitive to the effects of dopamine compared to other tasks [<xref rid="b0110" ref-type="bibr">22</xref>]. We used [<sup>11</sup>C]-a-(+)-[<sup>11</sup>C]dihydrotetrabenazine ([<sup>11</sup>C]DTBZ), a positron emission tomography (PET) radioligand that targets the type-2 vesicular monoamine transporter (VMAT2), as a measure of nigrostriatal dopaminergic terminal integrity [<xref rid="b0115" ref-type="bibr">[23]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>]. Our hypothesis was that higher [<sup>11</sup>C]DTBZ PET binding would be associated with less decline in %GSC, and that this relationship would be of greater magnitude among those with PSRF for gait slowing.</p></sec><sec id="s0010"><label>2</label><title>Methods</title><sec id="s0015"><label>2.1</label><title>Study sample</title><p id="p0025">This was a cross-sectional study of community dwelling older adults living in Southwestern Pennsylvania. The study sample was recruited from two ongoing population-based prospective longitudinal studies: the Monongahela-Youghiogheny Healthy Aging Team study (MYHAT) and Study of Muscle, Mobility and Aging (SOMMA). Sample identification, recruitment, and inclusion/exclusion criteria have previously been described.</p><p id="p0030">Briefly, MYHAT [<xref rid="b0130" ref-type="bibr">26</xref>] is a population-based cohort study of older adults that identified potential participants via age-stratified random sampling from voter registration lists. MYHAT recruited individuals aged 65 and older who reside in selected small towns of southwest PA and were not living in a nursing home. Exclusion criteria are illness or vision/hearing impairment severe enough to preclude study participation, moderate or severe cognitive impairment defined by age-education-corrected scores&#160;&lt;&#160;21 on the Mini-Mental State Examination [<xref rid="b0135" ref-type="bibr">27</xref>] or inability to provide informed consent.</p><p id="p0035">SOMMA [<xref rid="b0140" ref-type="bibr">28</xref>] recruited age-eligible individuals identified via mailing lists, voter registration, or in university-sponsored registries. Oversampling of zip codes with greater racial and ethnic diversity was performed. SOMMA recruited individuals aged 70 and older living in Southwest PA who were able to walk 400&#160;m at a usual pace. Exclusion criteria were anticoagulation therapy, contraindications to MRI or muscle biopsy, inability to walk 0.25 miles or climb a flight of stairs, active cancer or an advanced chronic disease such as heart failure, renal failure on dialysis, Parkinson&#8217;s disease, or dementia.</p><p id="p0040">All individuals enrolled in MYHAT without self-reported diagnosis of PD were potentially eligible. Individuals in SOMMA who had successfully completed muscle biopsy within the prior 12&#160;months were potentially eligible. For this analysis, we included only cognitively normal participants without diagnosed neurologic disorder; therefore, participants who self-reported stroke or who were classified as having mild cognitive impairment (MCI) or dementia were excluded, as were those with missing primary outcome or predictor in this analysis (see below).</p></sec><sec id="s0020"><label>2.2</label><title>Assessments</title><p id="p0045">The following assessments were administered; parent study-specific methods are detailed below where applicable. All assessments were obtained within 1&#160;year of imaging.<list list-type="simple" id="l0005"><list-item id="o0005"><label>&#8226;</label><p id="p0050">Demographics: age, race, ethnicity, sex at birth, and education as reported by the participant.</p></list-item><list-item id="o0010"><label>&#8226;</label><p id="p0055">Peripheral Systemic Risk Factors (PSRF): (1) Joint pain for at least 1&#160;month in the preceding year in the feet, toes, ankles, knees or hips was ascertained via self-report by participants. A participant was considered to have lower extremity joint pain if they responded yes to pain in any of these body regions. (2) Body mass index: weight (kg) and height (meters) were measured. Obesity was defined as body mass index&#160;&#8805;&#160;30 (3) Grip strength, a measure of muscle strength, was assessed in kilograms with Jamar dynamometer. Participants were asked to rest their arm on the table, bend their elbow, and squeeze the dynamometer at maximal effort. Two trials for each arm 15&#160;s apart were performed. For each participant the maximal value of right or left grip strength was determined and low grip strength was defined as being in the lowest sex-specific quartile of the sample from each parent study separately.</p></list-item><list-item id="o0015"><label>&#8226;</label><p id="p0060">Gait assessment: Time to complete walking of a 15-meter surface was used to compute walking speed in meters per second (m/s) under 2 conditions: (1) usual walking on an even surface. This is a clinically relevant measure [<xref rid="b0015" ref-type="bibr">3</xref>,<xref rid="b0020" ref-type="bibr">4</xref>,<xref rid="b0145" ref-type="bibr">29</xref>,<xref rid="b0150" ref-type="bibr">30</xref>] that is sensitive to age-related striatal denervation, and reliable; (2) usual walking on uneven surface: walking on a surface where 1.5&#160;cm high wood prisms arranged randomly at a density of 26 pieces/m<sup>2</sup> were placed underneath carpeting [<xref rid="b0155" ref-type="bibr">31</xref>]. Gait speed cost (%GSC) was calculated as [(speed on uneven &#8211; speed on even) / speed on even]x100. A negative percent change indicates the individual slowed down. Resiliency would be reflected in less slowing on transition from even to uneven (a %GSC closer to zero or one that is positive).</p></list-item><list-item id="o0020"><label>&#8226;</label><p id="p0065">Brain imaging: 3 Tesla magnetic resonance (MR) and [<sup>11</sup>C]DTBZ PET were simultaneously acquired on a whole-body human scanner that integrates a 3&#160;T MR and PET scanner (Siemens Biograph mMR, Siemens Medical Solutions USA, Malvern, PA).</p></list-item></list></p><p id="p0070"><italic toggle="yes">PET protocol</italic>: [<sup>11</sup>C]DTBZ was synthesized as previously described [<xref rid="b0160" ref-type="bibr">32</xref>] with high molar activity (59.9&#160;&#177;&#160;26.3&#160;MBq/nmol at time-of-injection, 3.81&#160;&#177;&#160;2.42&#160;&#956;g injected mass). [<sup>11</sup>C]DTBZ (573&#160;&#177;&#160;111 MBq) was injected intravenously as a slow bolus (20&#8211;30 sec) and list-mode acquisition of PET emission data commenced at the start of radiotracer injection and continued for 60&#160;min. 3&#160;T MR images included T1-weighted magnetization-prepared rapid gradient echo (MPRAGE) and Dixon sequences [<xref rid="b0165" ref-type="bibr">33</xref>]. PET emission data were reconstructed using filtered back projection (FBP) with Fourier rebinning into a dynamic series of 20 frames increasing in duration from 15 sec to 300 sec. Attenuation correction of PET emission data was performed analytically using previously described model-based methods [<xref rid="b0170" ref-type="bibr">34</xref>,<xref rid="b0175" ref-type="bibr">35</xref>]. Indices of [<sup>11</sup>C]DTBZ specific binding were derived using the non-invasive Logan graphical analysis method [<xref rid="b0180" ref-type="bibr">36</xref>] that estimates the radiotracer distribution volume ratio (DVR), which is defined as the equilibrium ratio of the total distribution volume (V<sub>T</sub>) in target tissues to the V<sub>T</sub> of a reference region devoid of VMAT2 (occipital cortex). The [<sup>11</sup>C]DTBZ imaging protocol and analysis method are simple to implement and well tolerated by participants with excellent reproducibility and reliability for estimating [<sup>11</sup>C]DTBZ specific binding [<xref rid="b0185" ref-type="bibr">37</xref>,<xref rid="b0190" ref-type="bibr">38</xref>]. For the present study, we report the [<sup>11</sup>C]DTBZ binding potential relative to non-displaceable binding, BP<sub>ND</sub> [<xref rid="b0195" ref-type="bibr">39</xref>], which is computed from the DVR using the simple relationship BP<sub>ND</sub>&#160;=&#160;DVR-1.</p><p id="p0075"><italic toggle="yes">Striatal subregions examined</italic>: volumes of interest (VOIs) for sampling of PET image data were defined on the MPRAGE MR series using an automated atlas-based method (CIC Atlas, Clinical Imaging Center, Imperial College, London, UK) [<xref rid="b0200" ref-type="bibr">40</xref>] that delineates over 100 cortical and subcortical regions in MR native space. These regions include the functional subdivisions of the striatum: the associative (anterior putamen, PreDorsal Caudate, PostDorsal Caudate), limbic (antero-ventral striatum) and sensorimotor (posterior putamen) [<xref rid="b0205" ref-type="bibr">41</xref>].</p><p id="p0080"><italic toggle="yes">Cortical volume and white matter hyperintensity quantitation</italic>: MRI volumes were distortion-corrected, registered, and segmented as described in [<xref rid="b0210" ref-type="bibr">42</xref>] using a combination of FSL and FreeSurfer analysis programs. Total and subcortical gray matter volumes were obtained via FreeSurfer [<xref rid="b0215" ref-type="bibr">43</xref>]. Regions were labeled with reference to the Desikan atlas [<xref rid="b0220" ref-type="bibr">44</xref>]. Gray matter volume was calculated as total gray matter volume/intracranial volume and subcortical gray matter volume as subcortical gray matter volume/intracranial volume. White matter hyperintensity on MRI, a measure of cerebral small vessel disease, was quantitated via automated segmentation methods as previously described [<xref rid="b0225" ref-type="bibr">45</xref>].<list list-type="simple" id="l0010"><list-item id="o0025"><label>&#8226;</label><p id="p0085">Cognition: participants were classified as normal cognition, MCI or dementia. In MYHAT, this determination was made based on Clinical Dementia Rating (CDR) scale score of&#160;&gt;&#160;0. In SOMMA, cognition was assessed with the Montreal Cognitive Assessment (MoCA). Participants were classified as normal, MCI, or dementia based on their MoCA score while accounting for age, sex, race, education level [<xref rid="b0230" ref-type="bibr">46</xref>]. This method was developed for individuals who identify as Hispanic, black, or white. In order to include all participants in the analysis, those who did not identify as Hispanic or black were assigned percentiles according to the normative data for those who identify as white (n&#160;=&#160;6 Asian, n&#160;=&#160;2 Native American, n&#160;=&#160;4 Unknown). Those with an education level of &#8220;Other&#8221;, &#8220;Some college&#8221;, and &#8220;Post college&#8221; were treated as &#8220;High School Education&#8221;, &#8220;Associate&#8217;s Degree&#8221;, and &#8220;Graduate Degree&#8221; respectively in the model. Normal cognition, MCI, and dementia were defined as&#160;&gt;&#160;10th percentile, &#8804;10<sup>th</sup> percentile but&#160;&gt;&#160;5th percentile, and&#160;&#8804;&#160;5th percentile respectively.</p></list-item><list-item id="o0030"><label>&#8226;</label><p id="p0090">Lifestyle factors: smoking history, alcohol intake in the prior year, and duration of walking with moderate intensity or greater per week as reported by the participant.</p></list-item><list-item id="o0035"><label>&#8226;</label><p id="p0095">Physical examination was conducted by a trained research coordinator or nurse trainee and included examination of cranial nerves, gross motor power, Romberg sign, and sensation to pinprick, vibratory sense, and light touch in the fingers and toes.</p></list-item><list-item id="o0040"><label>&#8226;</label><p id="p0100">Depression symptoms were assessed with modifications of the Center for Epidemiologic Studies Depression Scale (mCES-D). SOMMA administers the 10-item version of CES-D and MYHAT assesses depression with a modification of the scale in which responses are binary (yes/no). Responses in SOMMA for each item were dichotomized whereby responses of &#8220;Much of the time&#8221; or &#8220;Most or all of the time&#8221; were considered a response of &#8220;yes&#8221; for a given item, or otherwise no. A depression symptom total score was then calculated for each participant.</p></list-item><list-item id="o0045"><label>&#8226;</label><p id="p0105">Blood pressure: seated systolic and diastolic blood pressure in mm of Hg were assessed on the date of the baseline visit for each parent study; values include mean over two trials (in SOMMA) or one-time assessment (in MYHAT).</p></list-item><list-item id="o0050"><label>&#8226;</label><p id="p0110">Prescribed medications were ascertained via review, by study staff, of each medication bottle if they were brought by participants to the study visit or were otherwise self-reported by the participant. A total count, number of any prescriptions reported, was determined. Intake of antidepressants (which could theoretically impact [<sup>11</sup>C]DTBZ binding) [<xref rid="b0235" ref-type="bibr">47</xref>] within 30&#160;days of PET scan (SOMMA) or at the study visit closest to PET scan (MYHAT) was ascertained.</p></list-item><list-item id="o0055"><label>&#8226;</label><p id="p0115">Number of comorbidities: a count of 8 medical conditions, one point for each participant-reported condition: cancer, cardiac arrhythmia, chronic kidney disease, chronic obstructive pulmonary disease, coronary artery disease (myocardial infarction), congestive heart failure, diabetes, and stroke.</p></list-item></list></p><p id="p0120">The original study protocol aimed to assess pulmonary function with forced vital capacity but this was precluded during a portion of the COVID19 pandemic, hence this variable is not included.</p><sec id="s0025"><label>2.1.3</label><title>Statistical methods</title><p id="p0125">The primary predictor was [<sup>11</sup>C]DTBZ BP<sub>ND</sub> in each of the 3 striatal subregions (posterior putamen, anteroventral striatum, dorsal striatum). The primary outcome was %GSC. Gait speeds obtained during usual walking on even and uneven surface were examined as secondary outcomes.</p><p id="p0130">PSRF that may affect gait speed included joint pain (in hip or leg), obesity, and/or reduced grip strength. The group with one or more PSRF that may affect gait speed is hereto forth referred to as the &#8220;any PSRF&#8221; group, and the group with absence of any PSRF as the &#8220;no PSRF&#8221; group.</p><p id="p0135">Sample characteristics were summarized with descriptive statistics. The PSRF and no PSRF groups were compared with two-sample <italic toggle="yes">t</italic>-test, two-sample <italic toggle="yes">t</italic>-test with unequal variances, Wilcoxon rank sum test, chi-square test, or Fisher&#8217;s exact test as appropriate. Bivariate relationships between gait speed and age, and other demographic/clinical and imaging characteristics, all centered and standardized, were examined with simple linear regression models to obtain standardized beta coefficients. A similar approach was followed to examine the relationship between [<sup>11</sup>C]DTBZ BP<sub>ND</sub> and age and [<sup>11</sup>C]DTBZ BP<sub>ND</sub> and age.</p><p id="p0140">To determine if there was a significant relationship between gait speed and [<sup>11</sup>C]DTBZ BP<sub>ND</sub>, simple linear regressions were conducted with %GSC as the outcome, [<sup>11</sup>C]DTBZ BP<sub>ND</sub> in each of the 3 striatal subregions as predictors (each in separate models), and age at PET scan and sex as covariates. To examine whether the contribution of dopaminergic terminal integrity to %GSC varies according to presence or absence of any PSRF, an interaction term between DTBZ binding in each region and presence/absence of any PSRF was entered into the model, with age and sex as covariates. If the interaction was significant, models were repeated stratified by any PSRF and no PSRF.</p><p id="p0145">Models where the main association was significant in the sample as a whole or in any stratum were adjusted for additional confounders. Given the high number of potential confounders, and to address potential collinearity, variables were entered in subsequent steps: (1) any variable determined to be possibly (p&#160;&#8804;&#160;0.10) associated with the outcome in bivariate analysis; (2) log-transformed white matter hyperintensities; (3) taking antidepressant (4) number of comorbidities and (5) diabetes. Adjusted R<sup>2</sup> was used to determine percent of the variance in the outcome explained by the model.</p><p id="p0150">Assumptions for linear regression were checked by examining normality of distribution of the residuals for each model. All analyses were conducted with Stata version 18 (StataCorp, College Station, Tx, USA). A p-value&#160;&lt;&#160;0.05 was considered statistically significant and no adjustment was made for multiple comparisons.</p></sec></sec></sec><sec id="s0030"><label>3</label><title>Results</title><p id="p0155">Among potential participants, 644 were screened and 237 gave consent to participate and completed some study assessments (<xref rid="f0005" ref-type="fig">Fig. 1</xref>). Compared to those who consented, those who did not were older (73.94 (4.70) vs 75.39&#160;years (5.94), p&#160;=&#160;0.0009) and were more likely to have a level of education no higher than a High school/General educational development (15.19&#160;% vs 24.65&#160;%, p&#160;=&#160;0.003). All those excluded due to missing gait measures were from the SOMMA cohort and were more likely to be male compared to those who had a gait assessment (71.43&#160;% vs 37.81&#160;%, p&#160;&lt;&#160;0.001).<fig id="f0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>STROBE diagram for the study.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk00005" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p><p id="p0160">The final sample in the analysis included 197 participants. Characteristics of the final sample are shown in <xref rid="t0005" ref-type="table">Table 1</xref>. Compared to the MYHAT cohort, the SOMMA cohort were older, had a higher level of education, were less likely to have smoked, were less likely to be obese, less likely to have diabetes, and had a greater burden of white matter hyperintensities(<xref rid="s0060" ref-type="sec">Supplementary Table 1</xref>). Differences between cohorts in %GSC or [<sup>11</sup>C]DTBZ BP<sub>ND</sub> were not statistically significant.<table-wrap position="float" id="t0005" orientation="portrait"><label>Table 1</label><caption><p>Cohort characteristics in the sample as a whole and in those without vs with any peripheral systemic risk factor (PSRF) for gait slowing.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Variable<sup>i</sup></th><th colspan="1" rowspan="1">Total sample</th><th colspan="1" rowspan="1">No PSRF</th><th colspan="1" rowspan="1">Any PSRF</th><th colspan="1" rowspan="1">p-value<sup>ii</sup></th></tr></thead><tbody><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">N&#160;=&#160;197</td><td colspan="1" rowspan="1">N&#160;=&#160;67</td><td colspan="1" rowspan="1">N&#160;=&#160;130</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Age (years)</td><td colspan="1" rowspan="1">74.92 (4.53)</td><td colspan="1" rowspan="1">75.06 (4.97)</td><td colspan="1" rowspan="1">74.85 (4.30)</td><td colspan="1" rowspan="1">0.76</td></tr><tr><td colspan="1" rowspan="1">Sex</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">0.02</td></tr><tr><td colspan="1" rowspan="1">&#160;Male</td><td colspan="1" rowspan="1">75 (38.07&#160;%)</td><td colspan="1" rowspan="1">33 (49.25&#160;%)</td><td colspan="1" rowspan="1">42 (32.31&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td colspan="1" rowspan="1">122 (61.93&#160;%)</td><td colspan="1" rowspan="1">34 (50.75&#160;%)</td><td colspan="1" rowspan="1">88 (67.69&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Self-Identified Race</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">0.88</td></tr><tr><td colspan="1" rowspan="1">&#160;White</td><td colspan="1" rowspan="1">179 (90.86&#160;%)</td><td colspan="1" rowspan="1">63 (94.03&#160;%)</td><td colspan="1" rowspan="1">116 (89.23&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Black</td><td colspan="1" rowspan="1">15 (7.61&#160;%)</td><td colspan="1" rowspan="1">4 (5.97&#160;%)</td><td colspan="1" rowspan="1">11 (8.46&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Asian</td><td colspan="1" rowspan="1">1 (0.51&#160;%)</td><td colspan="1" rowspan="1">0 (0&#160;%)</td><td colspan="1" rowspan="1">1 (0.77&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Native American/Alaskan Native</td><td colspan="1" rowspan="1">1 (0.51&#160;%)</td><td colspan="1" rowspan="1">0 (0&#160;%)</td><td colspan="1" rowspan="1">1 (0.77&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Unknown</td><td colspan="1" rowspan="1">1 (0.51&#160;%)</td><td colspan="1" rowspan="1">0 (0&#160;%)</td><td colspan="1" rowspan="1">1 (0.77&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Education</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">0.005</td></tr><tr><td colspan="1" rowspan="1">&#160;Highschool/GED</td><td colspan="1" rowspan="1">32 (16.24&#160;%)</td><td colspan="1" rowspan="1">4 (5.97&#160;%)</td><td colspan="1" rowspan="1">28 (21.54&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;More than Highschool</td><td colspan="1" rowspan="1">164 (83.25&#160;%)</td><td colspan="1" rowspan="1">63 (94.03&#160;%)</td><td colspan="1" rowspan="1">101 (77.69&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Other</td><td colspan="1" rowspan="1">1 (0.51&#160;%)</td><td colspan="1" rowspan="1">0 (0&#160;%)</td><td colspan="1" rowspan="1">1 (0.77&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Smoking status</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">0.25</td></tr><tr><td colspan="1" rowspan="1">&#160;Never</td><td colspan="1" rowspan="1">105 (53.30&#160;%)</td><td colspan="1" rowspan="1">41 (61.19&#160;%)</td><td colspan="1" rowspan="1">64 (49.23&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Past</td><td colspan="1" rowspan="1">80 (40.61&#160;%)</td><td colspan="1" rowspan="1">22 (32.84&#160;%)</td><td colspan="1" rowspan="1">58 (44.62&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Current</td><td colspan="1" rowspan="1">12 (6.09&#160;%)</td><td colspan="1" rowspan="1">4 (5.97&#160;%)</td><td colspan="1" rowspan="1">8 (6.15&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Body mass index (kg/m<sup>2</sup>)</td><td colspan="1" rowspan="1">28.52 (5.45)</td><td colspan="1" rowspan="1">25.67 (2.67)</td><td colspan="1" rowspan="1">29.98 (5.93)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">Alcohol Intake Past Year</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">0.60</td></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="1" rowspan="1">48 (24.62&#160;%)</td><td colspan="1" rowspan="1">18 (26.87&#160;%)</td><td colspan="1" rowspan="1">30 (23.44&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1">147 (75.38&#160;%)</td><td colspan="1" rowspan="1">49 (73.13&#160;%)</td><td colspan="1" rowspan="1">98 (76.56&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Physical Activity: Hours Walked/Week</td><td colspan="1" rowspan="1">1.00 (0.00&#8211;3.50)</td><td colspan="1" rowspan="1">1.50 (0.00&#8211;3.50)</td><td colspan="1" rowspan="1">0.58 (0.00&#8211;3.50)</td><td colspan="1" rowspan="1">0.45</td></tr><tr><td colspan="1" rowspan="1">Depression Symptoms</td><td colspan="1" rowspan="1">0.00 (0.00&#8211;1.00)</td><td colspan="1" rowspan="1">0.00 (0.00&#8211;1.00)</td><td colspan="1" rowspan="1">0.00 (0.00&#8211;1.00)</td><td colspan="1" rowspan="1">0.34</td></tr><tr><td colspan="1" rowspan="1">Diabetes<sup>iii</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">0.44</td></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="1" rowspan="1">161 (82.14&#160;%)</td><td colspan="1" rowspan="1">57 (85.07&#160;%)</td><td colspan="1" rowspan="1">104 (80.62&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1">35 (17.86&#160;%)</td><td colspan="1" rowspan="1">10 (14.93&#160;%)</td><td colspan="1" rowspan="1">25 (19.38&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Systolic Blood Pressure<sup>iii</sup></td><td colspan="1" rowspan="1">131.41 (16.07)</td><td colspan="1" rowspan="1">130.98 (16.95)</td><td colspan="1" rowspan="1">131.65 (15.64)</td><td colspan="1" rowspan="1">0.80</td></tr><tr><td colspan="1" rowspan="1">Diastolic Blood Pressure<sup>iii</sup></td><td colspan="1" rowspan="1">71.78 (8.82)</td><td colspan="1" rowspan="1">71.97 (8.78)</td><td colspan="1" rowspan="1">71.68 (8.88)</td><td colspan="1" rowspan="1">0.84</td></tr><tr><td colspan="1" rowspan="1">Pulse</td><td colspan="1" rowspan="1">65.74 (9.80)</td><td colspan="1" rowspan="1">64.42 (8.88)</td><td colspan="1" rowspan="1">66.46 (10.24)</td><td colspan="1" rowspan="1">0.20</td></tr><tr><td colspan="1" rowspan="1">Medication Count<sup>ii</sup></td><td colspan="1" rowspan="1">4.00 (2.00&#8211;6.00)</td><td colspan="1" rowspan="1">3.00 (1.00&#8211;5.00)</td><td colspan="1" rowspan="1">5.00 (3.00&#8211;7.00)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">Treated with antidepressant</td><td colspan="1" rowspan="1">37 (18.78)</td><td colspan="1" rowspan="1">8 (11.94)</td><td colspan="1" rowspan="1">29 (22.31)</td><td colspan="1" rowspan="1">0.08</td></tr><tr><td colspan="1" rowspan="1">Number of comorbidities</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">0.29</td></tr><tr><td colspan="1" rowspan="1">&#160;0</td><td colspan="1" rowspan="1">97 (49.49&#160;%)</td><td colspan="1" rowspan="1">36 (53.73&#160;%)</td><td colspan="1" rowspan="1">61 (47.29&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;1</td><td colspan="1" rowspan="1">78 (39.80&#160;%)</td><td colspan="1" rowspan="1">27 (40.30&#160;%)</td><td colspan="1" rowspan="1">51 (39.53&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;2 or 3</td><td colspan="1" rowspan="1">21 (10.71&#160;%)</td><td colspan="1" rowspan="1">4 (5.97&#160;%)</td><td colspan="1" rowspan="1">17 (13.18&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Positive Romberg sign<sup>ii</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8722;-</td></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="1" rowspan="1">194 (100&#160;%)</td><td colspan="1" rowspan="1">66 (100&#160;%)</td><td colspan="1" rowspan="1">128 (100&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Vibratory sense reduced in toes<sup>iii</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">1.00</td></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="1" rowspan="1">77 (39.69&#160;%)</td><td colspan="1" rowspan="1">27 (40.30&#160;%)</td><td colspan="1" rowspan="1">50 (39.37&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1">117 (60.31&#160;%)</td><td colspan="1" rowspan="1">40 (59.70&#160;%)</td><td colspan="1" rowspan="1">77 (60.63&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Pinprick sensation reduced in toes<sup>iii</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">0.66</td></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="1" rowspan="1">189 (97.42&#160;%)</td><td colspan="1" rowspan="1">66 (98.51&#160;%)</td><td colspan="1" rowspan="1">123 (96.85&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1">5 (2.58&#160;%)</td><td colspan="1" rowspan="1">1 (1.49&#160;%)</td><td colspan="1" rowspan="1">4 (3.15&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Light touch sensation reduced<sup>iii</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">1.00</td></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="1" rowspan="1">192 (98.46&#160;%)</td><td colspan="1" rowspan="1">66 (98.51&#160;%)</td><td colspan="1" rowspan="1">126 (98.44&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1">3 (1.54&#160;%)</td><td colspan="1" rowspan="1">1 (1.49&#160;%)</td><td colspan="1" rowspan="1">2 (1.56&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">White matter hyperintensities (Normalized, mm<sup>3 iii</sup>)</td><td colspan="1" rowspan="1">0.007 (0.004&#8211;0.015)</td><td colspan="1" rowspan="1">0.007 (0.004&#8211;0.017)</td><td colspan="1" rowspan="1">0.007 (0.004&#8211;0.015)</td><td colspan="1" rowspan="1">0.99</td></tr><tr><td colspan="1" rowspan="1">Gray matter volume</td><td colspan="1" rowspan="1">0.336 (0.027)</td><td colspan="1" rowspan="1">0.338 (0.029)</td><td colspan="1" rowspan="1">0.335 (0.026)</td><td colspan="1" rowspan="1">0.39</td></tr><tr><td colspan="1" rowspan="1">Subcortical gray matter volume</td><td colspan="1" rowspan="1">0.034 (0.003)</td><td colspan="1" rowspan="1">0.034 (0.003)</td><td colspan="1" rowspan="1">0.034 (0.004)</td><td colspan="1" rowspan="1">0.36</td></tr><tr><td colspan="1" rowspan="1">Low Grip Strength<sup>iii</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8722;-</td></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="1" rowspan="1">135 (69.95&#160;%)</td><td colspan="1" rowspan="1">65 (100&#160;%)</td><td colspan="1" rowspan="1">70 (54.69&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1">58 (30.05&#160;%)</td><td colspan="1" rowspan="1">0 (0&#160;%)</td><td colspan="1" rowspan="1">58 (45.31&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Obese (body mass index&#160;&#8805;&#160;30&#160;kg/m<sup>2</sup>)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8722;-</td></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="1" rowspan="1">128 (64.97&#160;%)</td><td colspan="1" rowspan="1">67 (100&#160;%)</td><td colspan="1" rowspan="1">61 (46.92&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1">69 (35.03&#160;%)</td><td colspan="1" rowspan="1">0 (0&#160;%)</td><td colspan="1" rowspan="1">69 (53.08&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Pain for&#160;&#8805;&#160;1 month in hip or leg<sup>iii</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8722;-</td></tr><tr><td colspan="1" rowspan="1">&#160;No</td><td colspan="1" rowspan="1">137 (69.54&#160;%)</td><td colspan="1" rowspan="1">67 (100&#160;%)</td><td colspan="1" rowspan="1">70 (53.85&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Yes</td><td colspan="1" rowspan="1">60 (30.46&#160;%)</td><td colspan="1" rowspan="1">0 (0&#160;%)</td><td colspan="1" rowspan="1">60 (46.15&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Number of peripheral systemic risk factors for gait slowing<sup>iv</sup></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">&#8722;-</td></tr><tr><td colspan="1" rowspan="1">&#160;0</td><td colspan="1" rowspan="1">67 (34.01&#160;%)</td><td colspan="1" rowspan="1">67 (100&#160;%)</td><td colspan="1" rowspan="1">0 (0&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;1</td><td colspan="1" rowspan="1">77 (39.09&#160;%)</td><td colspan="1" rowspan="1">0 (0&#160;%)</td><td colspan="1" rowspan="1">77 (59.23&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;2</td><td colspan="1" rowspan="1">49 (24.87&#160;%)</td><td colspan="1" rowspan="1">0 (0&#160;%)</td><td colspan="1" rowspan="1">49 (37.69&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;3</td><td colspan="1" rowspan="1">4 (2.03&#160;%)</td><td colspan="1" rowspan="1">0 (0&#160;%)</td><td colspan="1" rowspan="1">4 (3.08&#160;%)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Gait speed measures (m/s)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Usual Walking Speed Even Surface</td><td colspan="1" rowspan="1">1.10 (0.20)</td><td colspan="1" rowspan="1">1.17 (0.20)</td><td colspan="1" rowspan="1">1.06 (0.19)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">&#160;Usual Walking Speed Uneven Surface</td><td colspan="1" rowspan="1">1.03 (0.21)</td><td colspan="1" rowspan="1">1.12 (0.20)</td><td colspan="1" rowspan="1">0.99 (0.20)</td><td colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td colspan="1" rowspan="1">% Gait speed cost uneven vs even (%GSC)</td><td colspan="1" rowspan="1">&#8722;5.37 (&#8722;9.34 to &#8722;3.00)</td><td colspan="1" rowspan="1">&#8722;5.03 (&#8722;6.73 to &#8722;1.95)</td><td colspan="1" rowspan="1">&#8722;5.77 (&#8722;10.06 to &#8722;3.27)</td><td colspan="1" rowspan="1">0.05</td></tr><tr><td colspan="1" rowspan="1">[<sup>11</sup>C]DTBZ BP<sub>ND</sub></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Posterior putamen (sensorimotor striatum)</td><td colspan="1" rowspan="1">2.44 (0.42)</td><td colspan="1" rowspan="1">2.38 (0.39)</td><td colspan="1" rowspan="1">2.46 (0.43)</td><td colspan="1" rowspan="1">0.20</td></tr><tr><td colspan="1" rowspan="1">&#160;Anteroventral striatum (limbic striatum)</td><td colspan="1" rowspan="1">1.63 (0.27)</td><td colspan="1" rowspan="1">1.62 (0.24)</td><td colspan="1" rowspan="1">1.64 (0.28)</td><td colspan="1" rowspan="1">0.60</td></tr><tr><td colspan="1" rowspan="1">&#160;Caudate and anterior putamen (associative striatum)</td><td colspan="1" rowspan="1">2.08 (0.34)</td><td colspan="1" rowspan="1">2.04 (0.29)</td><td colspan="1" rowspan="1">2.11 (0.35)</td><td colspan="1" rowspan="1">0.16</td></tr></tbody></table><table-wrap-foot><fn id="sp0025"><p><sup>i</sup>values shown are N (%), mean (SD), or median (interquartile range).</p></fn><fn id="sp0030"><p><sup>ii</sup>p-value from results comparing any PSRF to no PSRF groups with two-sample <italic toggle="yes">t</italic>-test, two-sample <italic toggle="yes">t</italic>-test with unequal variance, Wilcoxon rank sum test, chi-square test, or Fisher&#8217;s exact test as appropriate.</p></fn><fn id="sp0035"><p><sup>iii</sup>Missing values: Romberg n&#160;=&#160;3, vibratory sense n&#160;=&#160;3, light touch sensation n&#160;=&#160;3, alcohol intake n&#160;=&#160;2, physical activity n&#160;=&#160;6, diabetes assessment n&#160;=&#160;1, BP measurement n&#160;=&#160;27, white matter hyperintensities n&#160;=&#160;4, grip strength n&#160;=&#160;4, prescription count n&#160;=&#160;1.</p></fn><fn id="sp0040"><p><sup>iv</sup>All 3 systemic risk factors assessed in n&#160;=&#160;193; 2 impairments assessed in n&#160;=&#160;4. In 2 participants no impairments were present but not all 3 risk factors were assessed.</p></fn><fn id="sp0045"><p>BP = blood pressure, DTBZ BP<sub>ND</sub>&#160;=&#160;dihydrotetrabenazine binding potential, GED&#160;=&#160;general education diploma. PSRF&#160;=&#160;peripheral systemic risk factors.</p></fn></table-wrap-foot></table-wrap></p><p id="p0165">In the sample as a whole, age was inversely associated with the [<sup>11</sup>C]DTBZ BP<sub>ND</sub> in the posterior putamen, anteroventral striatum, and dorsal striatum (standardized &#946;&#160;=&#160;-0.234, p&#160;=&#160;0.001, standardized &#946;&#160;=&#160;-0.242, p&#160;=&#160;0.001, standardized &#946;&#160;=&#160;-0.197, p&#160;=&#160;0.006 respectively). Age was not associated with %GCS (standardized &#946;&#160;=&#160;0.094, p&#160;=&#160;0.188). Median %GSC was &#8722;5.37 (interquartile range (IQR) &#8722;9.34 to &#8722;3.0).</p><p id="p0170">Peripheral systemic risk factors for gait slowing were present in 130 (65.99&#160;%) and no PSRF were present in 67 (34.01&#160;%) (<xref rid="t0005" ref-type="table">Table 1</xref>). Compared to the no PSRF, the any PSRF were more likely to be female, to have lower education, higher mean BMI (as expected given absence of obesity in the no PSRF group by definition), and had a greater number of prescribed medications. Other characteristics did not significantly differ between groups. The group with any PSRF slowed down more on transition to uneven surface compared to the group with no PSRF (median (IQR) &#8722;5.77 (&#8722;10.06- to &#8722;3.27) vs &#8722;5.03 (&#8722;6.73 to &#8722;1.95) respectively), p&#160;=&#160;0.05). Other factors possibly (p&#160;&#8804;&#160;0.10) associated with %GSC in the sample as a whole included sex, race, education, physical activity, and medication count (<xref rid="t0010" ref-type="table">Table 2</xref>).<table-wrap position="float" id="t0010" orientation="portrait"><label>Table 2</label><caption><p>Relationship between gait speed cost from even to uneven surface and covariates/possible confounders in the cohort as a whole and in those with any peripheral systemic risk factors (PSRF) compared to those with no PSRF.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="3" rowspan="1">Total sample (n&#160;=&#160;197)</th><th colspan="3" rowspan="1">Any PSRF (n&#160;=&#160;130)</th><th colspan="3" rowspan="1">No PSRF (n&#160;=&#160;67)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Variables (standardized)</td><td colspan="1" rowspan="1">s&#946;<sup>i</sup></td><td colspan="1" rowspan="1">SE</td><td colspan="1" rowspan="1">p-value</td><td colspan="1" rowspan="1">s&#946;<sup>i</sup></td><td colspan="1" rowspan="1">SE</td><td colspan="1" rowspan="1">p-value</td><td colspan="1" rowspan="1">s&#946;<sup>i</sup></td><td colspan="1" rowspan="1">SE</td><td colspan="1" rowspan="1">p-value</td></tr><tr><td colspan="1" rowspan="1">Age</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.19</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">&#8722;0.03</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">0.73</td></tr><tr><td colspan="1" rowspan="1">Female sex</td><td colspan="1" rowspan="1">&#8722;0.38</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">&#8722;0.45</td><td colspan="1" rowspan="1">0.20</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">&#8722;0.14</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">0.42</td></tr><tr><td colspan="1" rowspan="1">Identified as non-White Race or Other</td><td colspan="1" rowspan="1">&#8722;1.01</td><td colspan="1" rowspan="1">0.24</td><td colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1">&#8722;1.33</td><td colspan="1" rowspan="1">0.29</td><td colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1">0.23</td><td colspan="1" rowspan="1">0.37</td><td colspan="1" rowspan="1">0.54</td></tr><tr><td colspan="1" rowspan="1">Education, Highschool/GED reference</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;More than Highschool/Other</td><td colspan="1" rowspan="1">0.39</td><td colspan="1" rowspan="1">0.19</td><td colspan="1" rowspan="1">0.05</td><td colspan="1" rowspan="1">0.25</td><td colspan="1" rowspan="1">0.24</td><td colspan="1" rowspan="1">0.30</td><td colspan="1" rowspan="1">0.71</td><td colspan="1" rowspan="1">0.36</td><td colspan="1" rowspan="1">0.05</td></tr><tr><td colspan="1" rowspan="1">Smoking, Never reference</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Past</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">0.23</td><td colspan="1" rowspan="1">0.19</td><td colspan="1" rowspan="1">0.20</td><td colspan="1" rowspan="1">0.35</td><td colspan="1" rowspan="1">0.29</td><td colspan="1" rowspan="1">0.19</td><td colspan="1" rowspan="1">0.13</td></tr><tr><td colspan="1" rowspan="1">&#160;Current</td><td colspan="1" rowspan="1">&#8722;0.05</td><td colspan="1" rowspan="1">0.31</td><td colspan="1" rowspan="1">0.88</td><td colspan="1" rowspan="1">&#8722;0.08</td><td colspan="1" rowspan="1">0.42</td><td colspan="1" rowspan="1">0.84</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">0.37</td><td colspan="1" rowspan="1">0.82</td></tr><tr><td colspan="1" rowspan="1">Alcohol Intake Past Year</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">0.73</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.23</td><td colspan="1" rowspan="1">0.74</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">0.20</td><td colspan="1" rowspan="1">0.76</td></tr><tr><td colspan="1" rowspan="1">Physical Activity: Hours Walked/Week</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">0.14</td></tr><tr><td colspan="1" rowspan="1">Depression Symptoms</td><td colspan="1" rowspan="1">&#8722;0.01</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.92</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">0.86</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">0.99</td></tr><tr><td colspan="1" rowspan="1">Diabetes</td><td colspan="1" rowspan="1">&#8722;0.29</td><td colspan="1" rowspan="1">0.19</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">&#8722;0.34</td><td colspan="1" rowspan="1">0.25</td><td colspan="1" rowspan="1">0.17</td><td colspan="1" rowspan="1">&#8722;0.11</td><td colspan="1" rowspan="1">0.25</td><td colspan="1" rowspan="1">0.67</td></tr><tr><td colspan="1" rowspan="1">Systolic BP</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">0.72</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">0.30</td><td colspan="1" rowspan="1">&#8722;0.11</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">0.17</td></tr><tr><td colspan="1" rowspan="1">Diastolic BP</td><td colspan="1" rowspan="1">&#8722;0.13</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">&#8722;0.16</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">0.14</td><td colspan="1" rowspan="1">&#8722;0.06</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">0.43</td></tr><tr><td colspan="1" rowspan="1">Medication Count</td><td colspan="1" rowspan="1">&#8722;0.19</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">&#8722;0.22</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">0.95</td></tr><tr><td colspan="1" rowspan="1">Treated with antidepressant</td><td colspan="1" rowspan="1">&#8722;0.19</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">0.30</td><td colspan="1" rowspan="1">&#8722;0.18</td><td colspan="1" rowspan="1">0.23</td><td colspan="1" rowspan="1">0.45</td><td colspan="1" rowspan="1">&#8722;0.03</td><td colspan="1" rowspan="1">0.27</td><td colspan="1" rowspan="1">0.91</td></tr><tr><td colspan="1" rowspan="1">Number of comorbidities, 0 reference</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;1</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">0.83</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">0.21</td><td colspan="1" rowspan="1">0.62</td><td colspan="1" rowspan="1">&#8722;0.07</td><td colspan="1" rowspan="1">0.19</td><td colspan="1" rowspan="1">0.69</td></tr><tr><td colspan="1" rowspan="1">&#160;2 or 3</td><td colspan="1" rowspan="1">&#8722;0.23</td><td colspan="1" rowspan="1">0.24</td><td colspan="1" rowspan="1">0.34</td><td colspan="1" rowspan="1">&#8722;0.21</td><td colspan="1" rowspan="1">0.30</td><td colspan="1" rowspan="1">0.49</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">0.38</td><td colspan="1" rowspan="1">0.95</td></tr><tr><td colspan="1" rowspan="1">Vibratory sense reduced in toes</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">0.97</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">0.20</td><td colspan="1" rowspan="1">0.61</td><td colspan="1" rowspan="1">&#8722;0.17</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">0.35</td></tr><tr><td colspan="1" rowspan="1">Pinprick sensation reduced in toes</td><td colspan="1" rowspan="1">&#8722;0.43</td><td colspan="1" rowspan="1">0.46</td><td colspan="1" rowspan="1">0.34</td><td colspan="1" rowspan="1">&#8722;0.25</td><td colspan="1" rowspan="1">0.57</td><td colspan="1" rowspan="1">0.65</td><td colspan="1" rowspan="1">&#8722;0.89</td><td colspan="1" rowspan="1">0.72</td><td colspan="1" rowspan="1">0.22</td></tr><tr><td colspan="1" rowspan="1">Light touch sensation reduced</td><td colspan="1" rowspan="1">&#8722;0.13</td><td colspan="1" rowspan="1">0.58</td><td colspan="1" rowspan="1">0.83</td><td colspan="1" rowspan="1">&#8722;0.39</td><td colspan="1" rowspan="1">0.79</td><td colspan="1" rowspan="1">0.62</td><td colspan="1" rowspan="1">0.41</td><td colspan="1" rowspan="1">0.72</td><td colspan="1" rowspan="1">0.57</td></tr><tr><td colspan="1" rowspan="1">Log-transformed white matter hyperintensities</td><td colspan="1" rowspan="1">&#8722;0.06</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">0.31</td><td colspan="1" rowspan="1">&#8722;0.12</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">0.21</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.82</td></tr><tr><td colspan="1" rowspan="1">Parent Study (SOMMA or MYHAT)</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">0.52</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">0.20</td><td colspan="1" rowspan="1">0.64</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1">0.92</td></tr><tr><td colspan="1" rowspan="1">Gray matter volume</td><td colspan="1" rowspan="1">&#8722;0.08</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.28</td><td colspan="1" rowspan="1">&#8722;0.09</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">0.38</td><td colspan="1" rowspan="1">&#8722;0.08</td><td colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1">0.33</td></tr><tr><td colspan="1" rowspan="1">Subcortical gray matter volume</td><td colspan="1" rowspan="1">&#8722;0.08</td><td colspan="1" rowspan="1">0.07</td><td colspan="1" rowspan="1">0.29</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">0.20</td><td colspan="1" rowspan="1">0.61</td><td colspan="1" rowspan="1">&#8722;0.09</td><td colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1">0.35</td></tr></tbody></table><table-wrap-foot><fn id="sp0055"><p><sup>i</sup>Each row represents results of a separate linear regression model.</p></fn><fn id="sp0060"><p>GED&#160;=&#160;general education diploma. PSRF&#160;=&#160;peripheral systemic risk factors. s&#946;&#160;=&#160;standardized beta coefficient.</p></fn></table-wrap-foot></table-wrap></p><p id="p0175">In the sample as a whole, [<sup>11</sup>C]DTBZ BP<sub>ND</sub> in none of the 3 striatal subregions were associated with %GSC after adjusting for age and sex (<xref rid="t0015" ref-type="table">Table 3</xref>). When an interaction term between presence/absence of any PSRF for gait slowing and [<sup>11</sup>C]DTBZ BP<sub>ND</sub> in each region was introduced into the model, the interaction was significant for posterior putamen only (p&#160;=&#160;0.03) but not for other subregions (<xref rid="t0015" ref-type="table">Table 3</xref>; <xref rid="f0010" ref-type="fig">Fig. 2</xref>)), indicating that the effect of posterior putamen on gait speed is influenced by the presence or absence of PSRF.<table-wrap position="float" id="t0015" orientation="portrait"><label>Table 3</label><caption><p>Relationship between gait speed cost on transition from even to uneven surface and DTBZ binding in the sample as a whole and interaction with presence or absence of any peripheral systemic risk factor for gait impairment, adjusted for age and sex.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"><hr/></th><th colspan="3" rowspan="1"><break/>Total Sample <sup>i</sup><hr/></th><th colspan="1" rowspan="1">Interaction term<break/>p-value<sup>ii</sup><hr/></th></tr><tr><th colspan="1" rowspan="1">[<sup>11</sup>C]DTBZ BP<sub>ND</sub> in striatal region</th><th colspan="1" rowspan="1">s&#946;</th><th colspan="1" rowspan="1">SE</th><th colspan="1" rowspan="1">p-value</th><th colspan="1" rowspan="1"/></tr></thead><tbody><tr><td colspan="1" rowspan="1">Posterior putamen (sensorimotor striatum)</td><td align="char" colspan="1" rowspan="1">0.01</td><td align="char" colspan="1" rowspan="1">0.07</td><td align="char" colspan="1" rowspan="1">0.18</td><td align="char" colspan="1" rowspan="1">0.03</td></tr><tr><td colspan="1" rowspan="1">Anteroventral striatum (limbic striatum)</td><td align="char" colspan="1" rowspan="1">0.02</td><td align="char" colspan="1" rowspan="1">0.08</td><td align="char" colspan="1" rowspan="1">0.77</td><td align="char" colspan="1" rowspan="1">0.29</td></tr><tr><td colspan="1" rowspan="1">Caudate and anterior putamen (associative striatum)</td><td align="char" colspan="1" rowspan="1">0.10</td><td align="char" colspan="1" rowspan="1">0.07</td><td align="char" colspan="1" rowspan="1">0.19</td><td align="char" colspan="1" rowspan="1">0.06</td></tr></tbody></table><table-wrap-foot><fn id="sp0070"><p><sup>i</sup>Linear regression model consisting of: gait speed cost on transition from even to uneven surface (outcome), [<sup>11</sup>C]DTBZ BP<sub>ND</sub> in specified striatal region, age, and sex.</p></fn><fn id="sp0075"><p><sup>ii</sup>Linear regression model consisting of: gait speed cost on transition from even to uneven surface (outcome), [<sup>11</sup>C]DTBZ BP<sub>ND</sub> in specified striatal region, age, and sex, presence of any risk factor, and interaction term between risk factor present (yes/no) and [<sup>11</sup>C]DTBZ BP<sub>ND</sub> in specified striatal region</p></fn><fn id="sp0080"><p>DTBZ BP<sub>ND</sub>&#160;=&#160;dihydrotetrabenazine binding potential. PSRF&#160;=&#160;peripheral systemic risk factors. s&#946;&#160;=&#160;standardized beta coefficient. SE&#160;=&#160;standard error.</p></fn></table-wrap-foot></table-wrap><fig id="f0010" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>(A) Full results of regression model examining interaction between PSRF and posterior putamen on % gait speed cost on transition from even to uneven surface, adjusting for age and sex and (B) graphical depiction of interaction between presence of PSRF and posterior putamen when holding age and sex constant.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="lk00010" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0180">Accordingly, we proceeded to further examine the relationship between %GSC and posterior putamen [<sup>11</sup>C]DTBZ BP<sub>ND</sub> in the any PSRF group. Associations between usual gait speeds on even or uneven surface and [<sup>11</sup>C]DTBZ BP<sub>ND</sub> in each of the striatal subregions were not significant and the interaction terms were not significant (<xref rid="s0060" ref-type="sec">Supplementary Table 2</xref>).</p><p id="p0185">Among the group with any PSRF for gait slowing, posterior putamen [<sup>11</sup>C]DTBZ BP<sub>ND</sub> was significantly associated with %GSC, independent of age and sex (<xref rid="t0020" ref-type="table">Table 4</xref>, Model 1). The association was also independent of confounders selected using bivariate models (<xref rid="t0015" ref-type="table">Table 3</xref>): race, amount of moderate walking per week, medication count, and education (<xref rid="t0020" ref-type="table">Table 4</xref>, Model 2). In addition, the association remained independent when intake of antidepressant (which could affect [<sup>11</sup>C]DTBZ BP<sub>ND</sub>) was added to the model (Model 3). However, when other confounders selected a priori (white matter hyperintensities, number of comorbidities,) were adjusted for, the relationship between posterior putamen and %GSC was no longer significant (<xref rid="t0020" ref-type="table">Table 4</xref>, models 4&#8211;6). Model 2 explained about 21.8&#160;% of the variance of %GSC. In this model, when adjusting for covariates, the variables that were significantly (p&#160;&lt;&#160;0.05) and independently associated with higher %GSC (less slowing down) in those with any PSRF were higher posterior putamen DTBZ BP<sub>ND,</sub> younger age, identifying as white race, and lower number of prescribed medications.<table-wrap position="float" id="t0020" orientation="portrait"><label>Table 4</label><caption><p>Among those with any peripheral systemic risk factor for gait slowing (n&#160;=&#160;130), results of multivariable regression with % gait speed cost on transition from uneven to even surface as outcome and PET-derived index of VMAT2 availability in the posterior putamen as the predictor.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">Standardized &#946;</th><th colspan="1" rowspan="1">SE</th><th colspan="1" rowspan="1">p-value</th><th colspan="1" rowspan="1">Adjusted R<sup>2</sup></th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><bold>Model 1 (n&#160;=&#160;130)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.077</td></tr><tr><td colspan="1" rowspan="1">&#160;Posterior putamen DBTZ BP<sub>ND</sub></td><td align="char" colspan="1" rowspan="1">0.233</td><td align="char" colspan="1" rowspan="1">0.093</td><td align="char" colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Age</td><td align="char" colspan="1" rowspan="1">0.207</td><td align="char" colspan="1" rowspan="1">0.101</td><td align="char" colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td align="char" colspan="1" rowspan="1">&#8722;0.460</td><td align="char" colspan="1" rowspan="1">0.20</td><td align="char" colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Constant</td><td align="char" colspan="1" rowspan="1">0.185</td><td align="char" colspan="1" rowspan="1">0.164</td><td align="char" colspan="1" rowspan="1">0.26</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Model 2 (N&#160;=&#160;125)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.218</td></tr><tr><td colspan="1" rowspan="1">&#160;Posterior putamen DBTZ BP<sub>ND</sub></td><td align="char" colspan="1" rowspan="1">0.198</td><td align="char" colspan="1" rowspan="1">0.092</td><td align="char" colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Age</td><td align="char" colspan="1" rowspan="1">0.224</td><td align="char" colspan="1" rowspan="1">0.097</td><td align="char" colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td align="char" colspan="1" rowspan="1">&#8722;0.262</td><td align="char" colspan="1" rowspan="1">0.197</td><td align="char" colspan="1" rowspan="1">0.19</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Identified as non-white</td><td align="char" colspan="1" rowspan="1">&#8722;1.112</td><td align="char" colspan="1" rowspan="1">0.293</td><td align="char" colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Physical Activity: Hrs Walked/Week</td><td align="char" colspan="1" rowspan="1">0.092</td><td align="char" colspan="1" rowspan="1">0.087</td><td align="char" colspan="1" rowspan="1">0.29</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Medication Count</td><td align="char" colspan="1" rowspan="1">&#8722;0.201</td><td align="char" colspan="1" rowspan="1">0.089</td><td align="char" colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Education (&lt;HS reference)</td><td align="char" colspan="1" rowspan="1">0.286</td><td align="char" colspan="1" rowspan="1">0.223</td><td align="char" colspan="1" rowspan="1">0.2</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Constant</td><td align="char" colspan="1" rowspan="1">&#8722;0.287</td><td align="char" colspan="1" rowspan="1">0.435</td><td align="char" colspan="1" rowspan="1">0.51</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Model 3 (N&#160;=&#160;125)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.212</td></tr><tr><td colspan="1" rowspan="1">&#160;Posterior putamen DBTZ BP<sub>ND</sub></td><td align="char" colspan="1" rowspan="1">0.202</td><td align="char" colspan="1" rowspan="1">0.093</td><td align="char" colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Age</td><td align="char" colspan="1" rowspan="1">0.217</td><td align="char" colspan="1" rowspan="1">0.099</td><td align="char" colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td align="char" colspan="1" rowspan="1">&#8722;0.255</td><td align="char" colspan="1" rowspan="1">0.199</td><td align="char" colspan="1" rowspan="1">0.2</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Identified as non-white</td><td align="char" colspan="1" rowspan="1">&#8722;1.134</td><td align="char" colspan="1" rowspan="1">0.299</td><td align="char" colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Physical Activity: Hrs Walked/Week</td><td align="char" colspan="1" rowspan="1">0.086</td><td align="char" colspan="1" rowspan="1">0.088</td><td align="char" colspan="1" rowspan="1">0.33</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Medication Count</td><td align="char" colspan="1" rowspan="1">&#8722;0.187</td><td align="char" colspan="1" rowspan="1">0.097</td><td align="char" colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Education (&lt;HS reference)</td><td align="char" colspan="1" rowspan="1">0.284</td><td align="char" colspan="1" rowspan="1">0.224</td><td align="char" colspan="1" rowspan="1">0.21</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Treated with antidepressant</td><td align="char" colspan="1" rowspan="1">&#8722;0.096</td><td align="char" colspan="1" rowspan="1">0.242</td><td align="char" colspan="1" rowspan="1">0.69</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Constant</td><td align="char" colspan="1" rowspan="1">&#8722;0.268</td><td align="char" colspan="1" rowspan="1">0.439</td><td align="char" colspan="1" rowspan="1">0.54</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Model 4 (N&#160;=&#160;122)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.232</td></tr><tr><td colspan="1" rowspan="1">&#160;Posterior putamen DBTZ BP<sub>ND</sub></td><td align="char" colspan="1" rowspan="1">0.161</td><td align="char" colspan="1" rowspan="1">0.094</td><td align="char" colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Age</td><td align="char" colspan="1" rowspan="1">0.239</td><td align="char" colspan="1" rowspan="1">0.103</td><td align="char" colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td align="char" colspan="1" rowspan="1">&#8722;0.293</td><td align="char" colspan="1" rowspan="1">0.199</td><td align="char" colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Identified as non-white</td><td align="char" colspan="1" rowspan="1">&#8722;1.088</td><td align="char" colspan="1" rowspan="1">0.293</td><td align="char" colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Physical Activity: Hrs Walked/Week</td><td align="char" colspan="1" rowspan="1">0.094</td><td align="char" colspan="1" rowspan="1">0.087</td><td align="char" colspan="1" rowspan="1">0.28</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Medication Count</td><td align="char" colspan="1" rowspan="1">&#8722;0.214</td><td align="char" colspan="1" rowspan="1">0.092</td><td align="char" colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Education (&lt;HS reference)</td><td align="char" colspan="1" rowspan="1">0.305</td><td align="char" colspan="1" rowspan="1">0.226</td><td align="char" colspan="1" rowspan="1">0.18</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Log-transformed white matter hyperintensities</td><td align="char" colspan="1" rowspan="1">&#8722;0.152</td><td align="char" colspan="1" rowspan="1">0.090</td><td align="char" colspan="1" rowspan="1">0.09</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Constant</td><td align="char" colspan="1" rowspan="1">&#8722;1.043</td><td align="char" colspan="1" rowspan="1">0.591</td><td align="char" colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Model 5 (N&#160;=&#160;125)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.225</td></tr><tr><td colspan="1" rowspan="1">&#160;Posterior putamen DBTZ BP<sub>ND</sub></td><td align="char" colspan="1" rowspan="1">0.166</td><td align="char" colspan="1" rowspan="1">0.094</td><td align="char" colspan="1" rowspan="1">0.08</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Age</td><td align="char" colspan="1" rowspan="1">0.216</td><td align="char" colspan="1" rowspan="1">0.097</td><td align="char" colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td align="char" colspan="1" rowspan="1">&#8722;0.290</td><td align="char" colspan="1" rowspan="1">0.199</td><td align="char" colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Identified as non-White Race</td><td align="char" colspan="1" rowspan="1">&#8722;1.173</td><td align="char" colspan="1" rowspan="1">0.297</td><td align="char" colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Physical Activity: Hrs Walked/Week</td><td align="char" colspan="1" rowspan="1">0.093</td><td align="char" colspan="1" rowspan="1">0.086</td><td align="char" colspan="1" rowspan="1">0.29</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Medication Count</td><td align="char" colspan="1" rowspan="1">&#8722;0.204</td><td align="char" colspan="1" rowspan="1">0.089</td><td align="char" colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Education</td><td align="char" colspan="1" rowspan="1">0.337</td><td align="char" colspan="1" rowspan="1">0.225</td><td align="char" colspan="1" rowspan="1">0.14</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Number of Comorbidities (0 ref)</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;1</td><td align="char" colspan="1" rowspan="1">0.254</td><td align="char" colspan="1" rowspan="1">0.201</td><td align="char" colspan="1" rowspan="1">0.21</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;2 or 3</td><td align="char" colspan="1" rowspan="1">&#8722;0.198</td><td align="char" colspan="1" rowspan="1">0.276</td><td align="char" colspan="1" rowspan="1">0.48</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Constant</td><td align="char" colspan="1" rowspan="1">&#8722;0.424</td><td align="char" colspan="1" rowspan="1">0.463</td><td align="char" colspan="1" rowspan="1">0.36</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><bold>Model 6 (N&#160;=&#160;125)</bold></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td align="char" colspan="1" rowspan="1">0.211</td></tr><tr><td colspan="1" rowspan="1">&#160;Posterior putamen DBTZ BP<sub>ND</sub></td><td align="char" colspan="1" rowspan="1">0.199</td><td align="char" colspan="1" rowspan="1">0.093</td><td align="char" colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Age</td><td align="char" colspan="1" rowspan="1">0.223</td><td align="char" colspan="1" rowspan="1">0.098</td><td align="char" colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Female</td><td align="char" colspan="1" rowspan="1">&#8722;0.264</td><td align="char" colspan="1" rowspan="1">0.198</td><td align="char" colspan="1" rowspan="1">0.19</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Identified as non-White Race</td><td align="char" colspan="1" rowspan="1">&#8722;1.104</td><td align="char" colspan="1" rowspan="1">0.301</td><td align="char" colspan="1" rowspan="1">&lt;0.001</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Physical Activity: Hrs Walked/Week</td><td align="char" colspan="1" rowspan="1">0.092</td><td align="char" colspan="1" rowspan="1">0.087</td><td align="char" colspan="1" rowspan="1">0.29</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Medication Count</td><td align="char" colspan="1" rowspan="1">&#8722;0.199</td><td align="char" colspan="1" rowspan="1">0.091</td><td align="char" colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Education</td><td align="char" colspan="1" rowspan="1">0.282</td><td align="char" colspan="1" rowspan="1">0.226</td><td align="char" colspan="1" rowspan="1">0.22</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Diabetes</td><td align="char" colspan="1" rowspan="1">&#8722;0.031</td><td align="char" colspan="1" rowspan="1">0.235</td><td align="char" colspan="1" rowspan="1">0.90</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#160;Constant</td><td align="char" colspan="1" rowspan="1">&#8722;0.273</td><td align="char" colspan="1" rowspan="1">0.450</td><td align="char" colspan="1" rowspan="1">0.54</td><td colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>DTBZ BP<sub>ND</sub>&#160;=&#160;dihydrotetrabenazine binding potential. HS = highschool. SE&#160;=&#160;standard error.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s0035"><label>4</label><title>Discussion</title><p id="p0190">We found that cross-sectionally, the relationship between striatal dopaminergic terminal integrity and slowing down of gait on transition from an even to an uneven surface varied according to presence or absence of a PSRF. Importantly, this relationship was found for %GSC but not walking speeds on an even or uneven surface. Among the 3 striatal subregions examined, this relationship was only present for the posterior putamen, consistent with the increased demand on sensorimotor integration required for complex walking tasks [<xref rid="b0110" ref-type="bibr">22</xref>]. Change in walking speed on surface transition is a possible measure of real-world perturbations in walking speed as may be encountered by an older adult navigating ground where the surface could change unpredictably from even to uneven [<xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>], such as on a sidewalk. Slowing down on surface transitions could be more predictive of fall risk [<xref rid="b0240" ref-type="bibr">48</xref>] and underlying neuropathology [<xref rid="b0105" ref-type="bibr">21</xref>] compared to other gait measures. While posterior putamen [<sup>11</sup>C]DTBZ BP<sub>ND</sub> was not associated with gait speed measures in the sample as a whole, in the group with a PSRF, there was a significant relationship with %GSC.</p><p id="p0195">Only among individuals with joint pain, obesity, and/or low grip strength, greater nigral dopaminergic terminal integrity was associated with less slowing down during the transition from even to uneven surface. To date, several lines of evidence have indicated a relationship between the dopaminergic system and gait abnormalities in older adults without diagnosed neurologic diseases. The catechol-o-methyl transferase genotype, an enzyme that metabolizes dopamine and that is highly expressed in the prefrontal cortex, has consistently been associated with gait speed cross-sectionally and predicts decline in gait speed in older adults [<xref rid="b0245" ref-type="bibr">[49]</xref>, <xref rid="b0250" ref-type="bibr">[50]</xref>, <xref rid="b0255" ref-type="bibr">[51]</xref>]. Recognizing that catechol-o-methyl transferase genotype is only an indirect reflection of CNS dopaminergic neurotransmission, and that it predominantly may influence prefrontal cortex and not striatal dopamine and other catecholamines, additional data were garnered from imaging studies in healthy adults without diagnosed neurologic diseases. Reductions in binding of PET radioligands for the dopamine transporter (DAT) have been associated with reduced gait speed [<xref rid="b0070" ref-type="bibr">14</xref>,<xref rid="b0260" ref-type="bibr">52</xref>]. Similar investigations have provided evidence for the potential of dopaminergic neurotransmission to provide compensation to other central and peripheral contributors to gait impairment. In one study [<xref rid="b0075" ref-type="bibr">15</xref>], while catechol-o-methyl transferase genotype was not associated with walking speed, the genotype modified the relationship between white matter hyperintensities and gait speed. Specifically, an association between white matter hyperintensities and gait speed was present in homozygous or heterozygous Val carriers but not Met/Met homozygotes [<xref rid="b0075" ref-type="bibr">15</xref>]. These results were interpreted as higher levels of prefrontal cortex dopamine in those with Met/Met genotype conferring compensation for white matter hyperintensities on gait speed [<xref rid="b0075" ref-type="bibr">15</xref>]. In addition, striatal DAT binding was shown to attenuate the relationship between white matter hyperintensities and parkinsonian signs [<xref rid="b0260" ref-type="bibr">52</xref>].</p><p id="p0200">Nigrostriatal dopaminergic neurotransmission regulates the automated execution of overlearned motor tasks via its connections with sensorimotor cortical and subcortical areas [<xref rid="b0265" ref-type="bibr">53</xref>]. Peripheral systemic risk factors for gait slowing such as joint pain, obesity, or reduced muscle strength make walking more demanding, eventually exceeding the capacity of the sensorimotor network for habitual control of overlearned movements. In such individuals with PSRF, the networks that modulate gait may call on the dopaminergic system to help compensate for the PSRF via higher sensorimotor connectivity, thus increasing automaticity of walking. That is, a stronger sensorimotor control system could offer at least some compensation to the demands imposed by PSRF, and promoting walking performance in a taxing environment such as transitions from even to uneven surfaces. Consistent with this, we found a relationship between posterior putamen, the sensorimotor region of the striatum, but not the anteroventral striatum which mainly projects to the limbic regions or associative striatum which mainly projects to the prefrontal cortex. In a mouse model, higher nigrostriatal dopaminergic levels had a net effect of facilitating striato-pallidum-thalamic excitatory outputs to primary sensorimotor regions, promoting ease and fluidity of movements, and initiation and execution of coordinated sequences of musculoskeletal activations [<xref rid="b0270" ref-type="bibr">54</xref>]. Preliminary data supporting this model in humans comes from studies in Parkinson&#8217;s disease, where dopaminergic neurotransmission was associated with microstructural and functional connectivity of sensorimotor networks [<xref rid="b0275" ref-type="bibr">[55]</xref>, <xref rid="b0280" ref-type="bibr">[56]</xref>, <xref rid="b0285" ref-type="bibr">[57]</xref>, <xref rid="b0290" ref-type="bibr">[58]</xref>, <xref rid="b0295" ref-type="bibr">[59]</xref>, <xref rid="b0300" ref-type="bibr">[60]</xref>]. In future studies we will pursue mechanistic investigations utilizing functional connectivity imaging to further test this model in older adults without diagnosed neurologic disorders. In addition, it will be important to consider the effect of other neurotransmitter systems, in particular the cholinergic system, on sensorimotor integration, whether independently, or in interaction with the dopaminergic system [<xref rid="b0305" ref-type="bibr">61</xref>,<xref rid="b0310" ref-type="bibr">62</xref>]. This has implications both in older adults without underlying neurodegeneration, and could inform treatments to improve resiliency of gait in individuals with neurodegenerative disorders including both Alzheimer&#8217;s [<xref rid="b0315" ref-type="bibr">63</xref>] and Parkinson&#8217;s disease [<xref rid="b0320" ref-type="bibr">64</xref>,<xref rid="b0325" ref-type="bibr">65</xref>].</p><p id="p0205">Posterior putamen [<sup>11</sup>C]DTBZ BP<sub>ND</sub> and %GSC were independently associated among those with PSRF, and this relationship remained significant after adjustment for several possible confounders. Older age was inversely associated with [<sup>11</sup>C]DTBZ BP<sub>ND</sub>, as expected given the established age-dependent decline in dopaminergic neurotransmission [<xref rid="b0070" ref-type="bibr">14</xref>]. However, in those with PSRF, the association of [<sup>11</sup>C]DTBZ BP<sub>ND</sub> with %GSC was independent of age, indicating the influence of dopaminergic neurotransmission of gait speed is not entirely explained by older age. When adjusting (in separate models) for race, physical activity, medications, and education the relationship remained similar, as it did for diabetes. However, when adjusting for cerebral small vessel disease or number of comorbidities, the relationship was no longer significant. This may suggest that with these additional CNS or systemic risk factors, dopaminergic neurotransmission is no longer able to offer compensation to effects on slowing of gait on transition. On the other hand, the findings may reflect collinearity between medical comorbidities and white matter hyperintensities measures, or medication count and comorbidities respectively.</p><p id="p0210">Due to the protocol limitations imposed during the COVID19 pandemic in 2020&#8211;2021, we were unable to assess pulmonary function, a known contributor to slow gait speed. Other contributors to slow gait speed that were not assessed in our study include (but are not limited to) vision impairment, peripheral vascular disease, atherosclerotic vascular disease, and blood-based measures of glucose dysmetabolism and renal dysfunction [<xref rid="b0045" ref-type="bibr">9</xref>]. Thus, it is not surprising that our model only explained at most about one-fifth of the variance in change in gait speed on transition from even to uneven surface. These findings reflect the multifactorial nature of gait speed slowing in older adults.</p><p id="p0215">Strengths of this study include a comprehensive assessment of risk factors for gait slowing including a neuroimaging protocol to assess for cerebral small vessel disease and GMV acquired simultaneously with PET. There are several limitations to this study. This was a cross-sectional study and does not allow us to determine causality&#8212;that is, to prove that it was dopaminergic neuron integrity that compensate for PSRF in older adults. In addition, only 30&#160;% of screened participants were included in the final analytic sample, and our study sample lacks racial and ethnic diversity. This is not uncommon in neuroimaging studies of older adults. Thus, our results may not be generalizable to the older adult population from which our sample was drawn. In addition, as mentioned, we only assessed 3 PSRF that may impact gait. Furthermore, while we were able to account for the possible effect of antidepressant intake on [<sup>11</sup>C]DTBZ BP<sub>ND</sub>, there are other medications such as stimulants which could impact VMAT2 binding that we did not have data for [<xref rid="b0235" ref-type="bibr">47</xref>,<xref rid="b0330" ref-type="bibr">66</xref>,<xref rid="b0335" ref-type="bibr">67</xref>].</p><p id="p0220">In conclusion, in this cross-sectional study of older adults, among those with joint pain, reduced grip strength, and/or obesity, greater dopaminergic neuron terminal integrity was significantly associated with less gait slowing when transitioning from an even to uneven surface. These results may inform future interventions to ameliorate gait performance by increasing dopamine in older adults with PSRF for gait impairment.</p></sec><sec id="s0040"><title>Declaration of Generative AI and AI-assisted technologies in the writing process</title><p id="p0225">No generative AI or AI-assisted technologies were used in the writing process.</p></sec><sec id="s0045"><title>CRediT authorship contribution statement</title><p id="p0230"><bold>Lana M. Chahine:</bold> Writing &#8211; original draft, Formal analysis. <bold>Andrea Rosso:</bold> Writing &#8211; review &amp; editing, Methodology. <bold>Ian Troidl:</bold> Writing &#8211; review &amp; editing, Validation, Project administration, Data curation. <bold>Mary Ganguli:</bold> Writing &#8211; review &amp; editing, Methodology. <bold>Anne Newman:</bold> Writing &#8211; review &amp; editing, Methodology, Funding acquisition. <bold>Steven Cummings:</bold> Writing &#8211; review &amp; editing, Funding acquisition. <bold>Stephanie Studenski:</bold> Writing &#8211; review &amp; editing. <bold>Brian Lopresti:</bold> Writing &#8211; review &amp; editing, Methodology. <bold>Sarah Royse:</bold> Writing &#8211; review &amp; editing, Methodology. <bold>Theodore Huppert:</bold> Writing &#8211; review &amp; editing, Methodology. <bold>Mark Redfern:</bold> Writing &#8211; review &amp; editing. <bold>Patrick J. Sparto:</bold> Writing &#8211; review &amp; editing. <bold>Nico I. Bohnen:</bold> Writing &#8211; review &amp; editing, Methodology, Funding acquisition. <bold>Caterina Rosano:</bold> Writing &#8211; original draft, Supervision, Methodology, Funding acquisition, Formal analysis.</p></sec><sec id="s0050"><title>Funding</title><p id="p0235">This work was supported by the National Institutes of Health grant U01AG061393 and 5R01AG075025. The Monongahela-Youghiogheny Healthy Aging Team (MYHAT) is funded by NIH R37 AG 023651.The Study of Muscle, Mobility and Aging is supported by funding from the National Institute on Aging, grant number AG059416. Study infrastructure support was funded in part by NIA Claude D. Pepper Older American Independence Centers at University of Pittsburgh (P30AG024827) and Wake Forest University (P30AG021332) and the Clinical and Translational Science Institutes, funded by the National Center for Advancing Translational Science, at Wake Forest University (UL1 0TR001420).</p></sec><sec sec-type="COI-statement" id="coi005"><title>Declaration of competing interest</title><p id="p0240">The authors declare no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name name-style="western"><surname>Rosso</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Studenski</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Aizenstein</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>Aging, the central nervous system, and mobility</article-title><source>J Gerontol A Biol Sci Med Sci</source><volume>68</volume><issue>11</issue><year>2013</year><fpage>1379</fpage><lpage>1386</lpage><pub-id pub-id-type="doi">10.1093/gerona/glt089</pub-id><pub-id pub-id-type="pmid">23843270</pub-id><pub-id pub-id-type="pmcid">PMC3805295</pub-id></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name name-style="western"><surname>Sorond</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Cruz-Almeida</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Viswanathan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scherzer</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>De Jager</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Aging, the central nervous system, and mobility in older adults: neural mechanisms of mobility impairment</article-title><source>J Gerontol A Biol Sci Med Sci</source><volume>70</volume><issue>12</issue><year>2015</year><fpage>1526</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1093/gerona/glv130</pub-id><pub-id pub-id-type="pmid">26386013</pub-id><pub-id pub-id-type="pmcid">PMC4643615</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name name-style="western"><surname>Perera</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Rosano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Satterfield</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Gait speed predicts incident disability: a pooled analysis</article-title><source>J Gerontol A Biol Sci Med Sci</source><volume>71</volume><issue>1</issue><year>2016</year><fpage>63</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1093/gerona/glv126</pub-id><pub-id pub-id-type="pmid">26297942</pub-id><pub-id pub-id-type="pmcid">PMC4715231</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name name-style="western"><surname>Studenski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perera</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rosano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Faulkner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Inzitari</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Gait speed and survival in older adults</article-title><source>J Am Med Assoc</source><volume>305</volume><issue>1</issue><year>2011</year><fpage>50</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1001/jama.2010.1923</pub-id><pub-id pub-id-type="pmcid">PMC3080184</pub-id><pub-id pub-id-type="pmid">21205966</pub-id></element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>N.B.</given-names></name></person-group><article-title>Gait disorders in older adults</article-title><source>J Am Geriatr Soc</source><volume>44</volume><issue>4</issue><year>1996</year><fpage>434</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.1996.tb06417.x</pub-id><pub-id pub-id-type="pmid">8636592</pub-id></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name name-style="western"><surname>Bindawas</surname><given-names>S.M.</given-names></name></person-group><article-title>Relationship between frequent knee pain, obesity, and gait speed in older adults: data from the Osteoarthritis Initiative</article-title><source>Clin Interv Aging</source><volume>11</volume><year>2016</year><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.2147/cia.S100546</pub-id><pub-id pub-id-type="pmid">26955266</pub-id><pub-id pub-id-type="pmcid">PMC4772994</pub-id></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name name-style="western"><surname>Figgins</surname><given-names>E.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Speechley</surname><given-names>M.</given-names></name><name name-style="western"><surname>Montero-Odasso</surname><given-names>M.</given-names></name></person-group><article-title>Associations between potentially modifiable and nonmodifiable risk factors and gait speed in middle- and older-aged adults: results from the Canadian longitudinal study on aging</article-title><source>J Gerontol A Biol Sci Med Sci</source><volume>76</volume><issue>10</issue><year>2021</year><fpage>e253</fpage><lpage>e263</lpage><pub-id pub-id-type="doi">10.1093/gerona/glab008</pub-id><pub-id pub-id-type="pmid">33420785</pub-id><pub-id pub-id-type="pmcid">PMC8522473</pub-id></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name name-style="western"><surname>Figgins</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pieruccini-Faria</surname><given-names>F.</given-names></name><name name-style="western"><surname>Speechley</surname><given-names>M.</given-names></name><name name-style="western"><surname>Montero-Odasso</surname><given-names>M.</given-names></name></person-group><article-title>Potentially modifiable risk factors for slow gait in community-dwelling older adults: a systematic review</article-title><source>Ageing Res Rev</source><volume>66</volume><year>2021</year><object-id pub-id-type="publisher-id">101253</object-id><pub-id pub-id-type="doi">10.1016/j.arr.2020.101253</pub-id><pub-id pub-id-type="pmid">33429086</pub-id></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name name-style="western"><surname>Rosso</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Boudreau</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Multisystem physiologic impairments and changes in gait speed of older adults</article-title><source>J Gerontol A Biol Sci Med Sci</source><volume>70</volume><issue>3</issue><year>2015</year><fpage>319</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1093/gerona/glu176</pub-id><pub-id pub-id-type="pmid">25380599</pub-id><pub-id pub-id-type="pmcid">PMC4351395</pub-id></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>McCreary</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Camicioli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>E.E.</given-names></name></person-group><article-title>Gait and falls in cerebral small vessel disease: a systematic review and meta-analysis</article-title><source>Age Ageing</source><volume>52</volume><issue>3</issue><year>2023</year><pub-id pub-id-type="doi">10.1093/ageing/afad011</pub-id><pub-id pub-id-type="pmcid">PMC10064981</pub-id><pub-id pub-id-type="pmid">37000039</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name name-style="western"><surname>Blumen</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Buchman</surname><given-names>A.S.</given-names></name></person-group><article-title>Adapting the reserve and resilience framework for motor and other aging phenotypes</article-title><source>Neurobiol Aging</source><volume>131</volume><year>2023</year><fpage>224</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2023.07.016</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name name-style="western"><surname>Rosso</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Studenski</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Longstreth</surname><given-names>W.T.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Brach</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Boudreau</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Rosano</surname><given-names>C.</given-names></name></person-group><article-title>Contributors to poor mobility in older adults: integrating white matter hyperintensities and conditions affecting other systems</article-title><source>J Gerontol A Biol Sci Med Sci</source><volume>72</volume><issue>9</issue><year>2017</year><fpage>1246</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1093/gerona/glw224</pub-id><pub-id pub-id-type="pmid">27816937</pub-id><pub-id pub-id-type="pmcid">PMC5861865</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name name-style="western"><surname>Gepshtein</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Snider</surname><given-names>J.</given-names></name><name name-style="western"><surname>Plank</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Poizner</surname><given-names>H.</given-names></name></person-group><article-title>Dopamine function and the efficiency of human movement</article-title><source>J Cogn Neurosci</source><volume>26</volume><issue>3</issue><year>2014</year><fpage>645</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1162/jocn_a_00503</pub-id><pub-id pub-id-type="pmid">24144250</pub-id><pub-id pub-id-type="pmcid">PMC4805420</pub-id></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name name-style="western"><surname>Cham</surname><given-names>R.</given-names></name><name name-style="western"><surname>Studenski</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Perera</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bohnen</surname><given-names>N.I.</given-names></name></person-group><article-title>Striatal dopaminergic denervation and gait in healthy adults</article-title><source>Exp Brain Res</source><volume>185</volume><issue>3</issue><year>2008</year><fpage>391</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1007/s00221-007-1161-3</pub-id><pub-id pub-id-type="pmid">17973106</pub-id></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name name-style="western"><surname>Rosso</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Bohnen</surname><given-names>N.I.</given-names></name><name name-style="western"><surname>Launer</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Aizenstein</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Yaffe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rosano</surname><given-names>C.</given-names></name></person-group><article-title>Vascular and dopaminergic contributors to mild parkinsonian signs in older adults</article-title><source>Neurology</source><volume>90</volume><issue>3</issue><year>2018</year><fpage>e223</fpage><lpage>e229</lpage><pub-id pub-id-type="doi">10.1212/wnl.0000000000004842</pub-id><pub-id pub-id-type="pmid">29247072</pub-id><pub-id pub-id-type="pmcid">PMC5772161</pub-id></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name name-style="western"><surname>Buchman</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Leurgans</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Nag</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J.A.</given-names></name></person-group><article-title>Cerebrovascular disease pathology and parkinsonian signs in old age</article-title><source>Stroke</source><volume>42</volume><issue>11</issue><year>2011</year><fpage>3183</fpage><lpage>3189</lpage><pub-id pub-id-type="doi">10.1161/strokeaha.111.623462</pub-id><pub-id pub-id-type="pmid">21885844</pub-id><pub-id pub-id-type="pmcid">PMC3202031</pub-id></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name name-style="western"><surname>Buchman</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Shulman</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Nag</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leurgans</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Nigral pathology and parkinsonian signs in elders without Parkinson disease</article-title><source>Ann Neurol</source><volume>71</volume><issue>2</issue><year>2012</year><fpage>258</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1002/ana.22588</pub-id><pub-id pub-id-type="pmid">22367997</pub-id><pub-id pub-id-type="pmcid">PMC3367476</pub-id></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Petrovitch</surname><given-names>H.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Markesbery</surname><given-names>W.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Parkinsonian signs and substantia nigra neuron density in decendents elders without PD</article-title><source>Ann Neurol</source><volume>56</volume><issue>4</issue><year>2004</year><fpage>532</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1002/ana.20226</pub-id><pub-id pub-id-type="pmid">15389895</pub-id></element-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name name-style="western"><surname>Menant</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Steele</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Menz</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Munro</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Lord</surname><given-names>S.R.</given-names></name></person-group><article-title>Effects of walking surfaces and footwear on temporo-spatial gait parameters in young and older people</article-title><source>Gait Posture</source><volume>29</volume><issue>3</issue><year>2009</year><fpage>392</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.gaitpost.2008.10.057</pub-id><pub-id pub-id-type="pmid">19041245</pub-id></element-citation></ref><ref id="b0100"><label>20</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name name-style="western"><surname>Menz</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Lord</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>R.C.</given-names></name></person-group><article-title>Age-related differences in walking stability</article-title><source>Age Ageing</source><volume>32</volume><issue>2</issue><year>2003</year><fpage>137</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1093/ageing/32.2.137</pub-id><pub-id pub-id-type="pmid">12615555</pub-id></element-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name name-style="western"><surname>Zukowski</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Fino</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Levin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Age and beta amyloid deposition impact gait speed, stride length, and gait smoothness while transitioning from an even to an uneven walking surface in older adults</article-title><source>Hum Mov Sci</source><volume>93</volume><year>2024</year><object-id pub-id-type="publisher-id">103175</object-id><pub-id pub-id-type="doi">10.1016/j.humov.2023.103175</pub-id><pub-id pub-id-type="pmcid">PMC11195422</pub-id><pub-id pub-id-type="pmid">38198920</pub-id></element-citation></ref><ref id="b0110"><label>22</label><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chastan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bair</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Resnick</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ferrucci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Studenski</surname><given-names>S.A.</given-names></name></person-group><article-title>The brain map of gait variability in aging, cognitive impairment and dementia-a systematic review</article-title><source>Neurosci Biobehav Rev</source><volume>74</volume><issue>Pt A</issue><year>2017</year><fpage>149</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2017.01.020</pub-id><pub-id pub-id-type="pmid">28115194</pub-id><pub-id pub-id-type="pmcid">PMC5303129</pub-id></element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name name-style="western"><surname>Bohnen</surname><given-names>N.I.</given-names></name><name name-style="western"><surname>Albin</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Koeppe</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Wernette</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Kilbourn</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Minoshima</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease</article-title><source>J Cereb Blood Flow Metab</source><volume>26</volume><issue>9</issue><year>2006</year><fpage>1198</fpage><lpage>1212</lpage><pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600276</pub-id><pub-id pub-id-type="pmid">16421508</pub-id></element-citation></ref><ref id="b0120"><label>24</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>H.V.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Shill</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Driver-Dunckley</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sabbagh</surname><given-names>M.N.</given-names></name><etal/></person-group><article-title>Clinicopathological correlation: dopamine and amyloid PET imaging with neuropathology in three subjects clinically diagnosed with Alzheimer's disease or dementia with lewy bodies</article-title><source>J Alzheimers Dis</source><volume>80</volume><issue>4</issue><year>2021</year><fpage>1603</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.3233/jad-200323</pub-id><pub-id pub-id-type="pmid">33720879</pub-id><pub-id pub-id-type="pmcid">PMC10109539</pub-id></element-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name name-style="western"><surname>Hsiao</surname><given-names>I.T.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W.Y.</given-names></name><name name-style="western"><surname>Wey</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Kung</surname><given-names>M.P.</given-names></name><etal/></person-group><article-title>Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography</article-title><source>JAMA Neurol</source><volume>71</volume><issue>6</issue><year>2014</year><fpage>758</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2014.290</pub-id><pub-id pub-id-type="pmid">24756323</pub-id></element-citation></ref><ref id="b0130"><label>26</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name name-style="western"><surname>Ganguli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Snitz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vander Bilt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.C.</given-names></name></person-group><article-title>How much do depressive symptoms affect cognition at the population level? The Monongahela-Youghiogheny Healthy Aging Team (MYHAT) study</article-title><source>Int J Geriatr Psychiatry</source><volume>24</volume><issue>11</issue><year>2009</year><fpage>1277</fpage><lpage>1284</lpage><pub-id pub-id-type="doi">10.1002/gps.2257</pub-id><pub-id pub-id-type="pmid">19340894</pub-id><pub-id pub-id-type="pmcid">PMC2784260</pub-id></element-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name name-style="western"><surname>Folstein</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Folstein</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>McHugh</surname><given-names>P.R.</given-names></name></person-group><article-title>&#8220;Mini-mental state&#8221;. A practical method for grading the cognitive state of patients for the clinician</article-title><source>J Psychiatr Res</source><volume>12</volume><issue>3</issue><year>1975</year><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">1202204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0022-3956(75)90026-6</pub-id></element-citation></ref><ref id="b0140"><label>28</label><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name name-style="western"><surname>Cummings</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Coen</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Hepple</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The study of muscle, mobility and aging (SOMMA). A unique cohort study about the cellular biology of aging and age-related loss of mobility</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2023</year><pub-id pub-id-type="doi">10.1093/gerona/glad052</pub-id><pub-id pub-id-type="pmcid">PMC10613002</pub-id><pub-id pub-id-type="pmid">36754371</pub-id></element-citation></ref><ref id="b0145"><label>29</label><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name name-style="western"><surname>Hardy</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Perera</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roumani</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Chandler</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Studenski</surname><given-names>S.A.</given-names></name></person-group><article-title>Improvement in usual gait speed predicts better survival in older adults</article-title><source>J Am Geriatr Soc</source><volume>55</volume><issue>11</issue><year>2007</year><fpage>1727</fpage><lpage>1734</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2007.01413.x</pub-id><pub-id pub-id-type="pmid">17916121</pub-id></element-citation></ref><ref id="b0150"><label>30</label><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name name-style="western"><surname>Perera</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mody</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Woodman</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Studenski</surname><given-names>S.A.</given-names></name></person-group><article-title>Meaningful change and responsiveness in common physical performance measures in older adults</article-title><source>J Am Geriatr Soc</source><volume>54</volume><issue>5</issue><year>2006</year><fpage>743</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1111/j.1532-5415.2006.00701.x</pub-id><pub-id pub-id-type="pmid">16696738</pub-id></element-citation></ref><ref id="b0155"><label>31</label><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name name-style="western"><surname>Thies</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Demott</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ashton-Miller</surname><given-names>J.A.</given-names></name></person-group><article-title>Influence of an irregular surface and low light on the step variability of patients with peripheral neuropathy during level gait</article-title><source>Gait Posture</source><volume>22</volume><issue>1</issue><year>2005</year><fpage>40</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.gaitpost.2004.06.006</pub-id><pub-id pub-id-type="pmid">15996590</pub-id></element-citation></ref><ref id="b0160"><label>32</label><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name name-style="western"><surname>Kilbourn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vander Borght</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jewett</surname><given-names>D.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>K.</given-names></name></person-group><article-title>Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific</article-title><source>Eur J Pharmacol</source><volume>278</volume><issue>3</issue><year>1995</year><fpage>249</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(95)00162-e</pub-id><pub-id pub-id-type="pmid">7589162</pub-id></element-citation></ref><ref id="b0165"><label>33</label><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name name-style="western"><surname>Dixon</surname><given-names>W.T.</given-names></name></person-group><article-title>Simple proton spectroscopic imaging</article-title><source>Radiology</source><volume>153</volume><issue>1</issue><year>1984</year><fpage>189</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1148/radiology.153.1.6089263</pub-id><pub-id pub-id-type="pmid">6089263</pub-id></element-citation></ref><ref id="b0170"><label>34</label><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name name-style="western"><surname>Izquierdo-Garcia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>F&#246;rster</surname><given-names>S.</given-names></name><name name-style="western"><surname>Benoit</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schachoff</surname><given-names>S.</given-names></name><name name-style="western"><surname>F&#252;rst</surname><given-names>S.</given-names></name><etal/></person-group><article-title>An SPM8-based approach for attenuation correction combining segmentation and nonrigid template formation: application to simultaneous PET/MR brain imaging</article-title><source>J Nucl Med</source><volume>55</volume><issue>11</issue><year>2014</year><fpage>1825</fpage><lpage>1830</lpage><pub-id pub-id-type="doi">10.2967/jnumed.113.136341</pub-id><pub-id pub-id-type="pmid">25278515</pub-id><pub-id pub-id-type="pmcid">PMC4246705</pub-id></element-citation></ref><ref id="b0175"><label>35</label><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name name-style="western"><surname>Koesters</surname><given-names>T.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Fenchel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hermosillo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Babb</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Dixon sequence with superimposed model-based bone compartment provides highly accurate PET/MR attenuation correction of the brain</article-title><source>J Nucl Med</source><volume>57</volume><issue>6</issue><year>2016</year><fpage>918</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.2967/jnumed.115.166967</pub-id><pub-id pub-id-type="pmid">26837338</pub-id><pub-id pub-id-type="pmcid">PMC4896499</pub-id></element-citation></ref><ref id="b0180"><label>36</label><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name name-style="western"><surname>Logan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Volkow</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Alexoff</surname><given-names>D.L.</given-names></name></person-group><article-title>Distribution volume ratios without blood sampling from graphical analysis of PET data</article-title><source>J Cereb Blood Flow Metab</source><volume>16</volume><issue>5</issue><year>1996</year><fpage>834</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1097/00004647-199609000-00008</pub-id><pub-id pub-id-type="pmid">8784228</pub-id></element-citation></ref><ref id="b0185"><label>37</label><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Holden</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Stoessl</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Samii</surname><given-names>A.</given-names></name><name name-style="western"><surname>Doudet</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Dobko</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects</article-title><source>J Nucl Med</source><volume>40</volume><issue>2</issue><year>1999</year><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">10025836</pub-id></element-citation></ref><ref id="b0190"><label>38</label><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name name-style="western"><surname>Sossi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Holden</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Krzywinski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stoessl</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Ruth</surname><given-names>T.J.</given-names></name></person-group><article-title>Analysis of four dopaminergic tracers kinetics using two different tissue input function methods</article-title><source>J Cereb Blood Flow Metab</source><volume>20</volume><issue>4</issue><year>2000</year><fpage>653</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1097/00004647-200004000-00002</pub-id><pub-id pub-id-type="pmid">10779009</pub-id></element-citation></ref><ref id="b0195"><label>39</label><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name name-style="western"><surname>Innis</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Delforge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gjedde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gunn</surname><given-names>R.N.</given-names></name><etal/></person-group><article-title>Consensus nomenclature for in vivo imaging of reversibly binding radioligands</article-title><source>J Cereb Blood Flow Metab</source><volume>27</volume><issue>9</issue><year>2007</year><fpage>1533</fpage><lpage>1539</lpage><pub-id pub-id-type="doi">10.1038/sj.jcbfm.9600493</pub-id><pub-id pub-id-type="pmid">17519979</pub-id></element-citation></ref><ref id="b0200"><label>40</label><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name name-style="western"><surname>Tziortzi</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Searle</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Tzimopoulou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salinas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Beaver</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Jenkinson</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy</article-title><source>Neuroimage</source><volume>54</volume><issue>1</issue><year>2011</year><fpage>264</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.06.044</pub-id><pub-id pub-id-type="pmid">20600980</pub-id></element-citation></ref><ref id="b0205"><label>41</label><element-citation publication-type="journal" id="h0205"><person-group person-group-type="author"><name name-style="western"><surname>Martinez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Slifstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Broft</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mawlawi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum</article-title><source>J Cereb Blood Flow Metab</source><volume>23</volume><issue>3</issue><year>2003</year><object-id pub-id-type="publisher-id">285&#8211;300.10.1097/01.Wcb.0000048520.34839.1a</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.WCB.0000048520.34839.1A</pub-id><pub-id pub-id-type="pmid">12621304</pub-id></element-citation></ref><ref id="b0210"><label>42</label><element-citation publication-type="journal" id="h0210"><person-group person-group-type="author"><name name-style="western"><surname>Glasser</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Sotiropoulos</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Coalson</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Fischl</surname><given-names>B.</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>The minimal preprocessing pipelines for the Human Connectome Project</article-title><source>Neuroimage</source><volume>80</volume><year>2013</year><fpage>105</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2013.04.127</pub-id><pub-id pub-id-type="pmid">23668970</pub-id><pub-id pub-id-type="pmcid">PMC3720813</pub-id></element-citation></ref><ref id="b0215"><label>43</label><element-citation publication-type="journal" id="h0215"><person-group person-group-type="author"><name name-style="western"><surname>Dale</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Fischl</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sereno</surname><given-names>M.I.</given-names></name></person-group><article-title>Cortical surface-based analysis I. Segmentation and surface reconstruction</article-title><source>Neuroimage</source><volume>9</volume><issue>2</issue><year>1999</year><fpage>179</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1006/nimg.1998.0395</pub-id><pub-id pub-id-type="pmid">9931268</pub-id></element-citation></ref><ref id="b0220"><label>44</label><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name name-style="western"><surname>Desikan</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>S&#233;gonne</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fischl</surname><given-names>B.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Dickerson</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Blacker</surname><given-names>D.</given-names></name><etal/></person-group><article-title>An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest</article-title><source>Neuroimage</source><volume>31</volume><issue>3</issue><year>2006</year><fpage>968</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2006.01.021</pub-id><pub-id pub-id-type="pmid">16530430</pub-id></element-citation></ref><ref id="b0225"><label>45</label><mixed-citation publication-type="other" id="h0225">Schmidt P, Wink L. LST: A Lesion Segmentation Tool for SPM. Manual/Documentation for Version 2, 2017. https://www.applied-statistics.de/lst.html.</mixed-citation></ref><ref id="b0230"><label>46</label><element-citation publication-type="journal" id="h0230"><person-group person-group-type="author"><name name-style="western"><surname>Sachs</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Chelune</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Rapp</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Couto</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Willard</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>Robust demographically-adjusted normative data for the Montreal Cognitive Assessment (MoCA): results from the systolic blood pressure intervention trial</article-title><source>Clin Neuropsychol</source><volume>36</volume><issue>8</issue><year>2022</year><fpage>2237</fpage><lpage>2259</lpage><pub-id pub-id-type="doi">10.1080/13854046.2021.1967450</pub-id><pub-id pub-id-type="pmid">34470584</pub-id><pub-id pub-id-type="pmcid">PMC8885785</pub-id></element-citation></ref><ref id="b0235"><label>47</label><element-citation publication-type="journal" id="h0235"><person-group person-group-type="author"><name name-style="western"><surname>Yasumoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Karasawa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2</article-title><source>Neurosci Lett</source><volume>454</volume><issue>3</issue><year>2009</year><fpage>229</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2009.03.049</pub-id><pub-id pub-id-type="pmid">19429089</pub-id></element-citation></ref><ref id="b0240"><label>48</label><element-citation publication-type="journal" id="h0240"><person-group person-group-type="author"><name name-style="western"><surname>Wenzel</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Holcomb</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>T.N.</given-names></name></person-group><article-title>Surface, but not age, impacts lower limb joint work during walking and stair ascent</article-title><source>J Funct Morphol Kinesiol</source><volume>8</volume><issue>4</issue><year>2023</year><pub-id pub-id-type="doi">10.3390/jfmk8040145</pub-id><pub-id pub-id-type="pmcid">PMC10594440</pub-id><pub-id pub-id-type="pmid">37873904</pub-id></element-citation></ref><ref id="b0245"><label>49</label><element-citation publication-type="journal" id="h0245"><person-group person-group-type="author"><name name-style="western"><surname>Mance</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rosso</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Studenski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bohnen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rosano</surname><given-names>C.</given-names></name></person-group><article-title>Catechol-O-methyltransferase genotype, frailty, and gait speed: the cardiovascular health study</article-title><source>Innov Aging</source><volume>4</volume><issue>Supplement_1</issue><year>2020</year><fpage>757</fpage><pub-id pub-id-type="doi">10.1093/geroni/igaa057.2729</pub-id></element-citation></ref><ref id="b0250"><label>50</label><element-citation publication-type="journal" id="h0250"><person-group person-group-type="author"><name name-style="western"><surname>Metti</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Rosano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Boudreau</surname><given-names>R.</given-names></name><name name-style="western"><surname>Massa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yaffe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Satterfield</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Catechol-O-methyltransferase genotype and gait speed changes over 10 years in older adults</article-title><source>J Am Geriatr Soc</source><volume>65</volume><issue>9</issue><year>2017</year><fpage>2016</fpage><lpage>2022</lpage><pub-id pub-id-type="doi">10.1111/jgs.14980</pub-id><pub-id pub-id-type="pmid">28640434</pub-id><pub-id pub-id-type="pmcid">PMC5603384</pub-id></element-citation></ref><ref id="b0255"><label>51</label><element-citation publication-type="journal" id="h0255"><person-group person-group-type="author"><name name-style="western"><surname>Sprague</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Rosso</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bohnen</surname><given-names>N.I.</given-names></name><name name-style="western"><surname>Rosano</surname><given-names>C.</given-names></name></person-group><article-title>Catechol-O-methyltransferase (COMT) polymorphism predicts rapid gait speed changes in healthy older adults</article-title><source>J Am Geriatr Soc</source><volume>69</volume><issue>11</issue><year>2021</year><fpage>3194</fpage><lpage>3202</lpage><pub-id pub-id-type="doi">10.1111/jgs.17351</pub-id><pub-id pub-id-type="pmid">34231207</pub-id><pub-id pub-id-type="pmcid">PMC8595534</pub-id></element-citation></ref><ref id="b0260"><label>52</label><mixed-citation publication-type="other" id="h0260">Rosano C, Metti AL, Rosso AL, Studenski S, Bohnen NI. Influence of striatal dopamine, cerebral small vessel disease, and other risk factors on age-related parkinsonian motor signs. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences.glz161 [pii] 2019.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/gerona/glz161</pub-id><pub-id pub-id-type="pmcid">PMC7328193</pub-id><pub-id pub-id-type="pmid">31425570</pub-id></mixed-citation></ref><ref id="b0265"><label>53</label><element-citation publication-type="journal" id="h0265"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hallett</surname><given-names>M.</given-names></name></person-group><article-title>The influence of normal human ageing on automatic movements</article-title><source>J Physiol</source><volume>562</volume><issue>Pt 2</issue><year>2005</year><fpage>605</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2004.076042</pub-id><pub-id pub-id-type="pmid">15513939</pub-id><pub-id pub-id-type="pmcid">PMC1665504</pub-id></element-citation></ref><ref id="b0270"><label>54</label><element-citation publication-type="journal" id="h0270"><person-group person-group-type="author"><name name-style="western"><surname>Panigrahi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Graves</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Vollmer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Dopamine is required for the neural representation and control of movement vigor</article-title><source>Cell</source><volume>162</volume><issue>6</issue><year>2015</year><fpage>1418</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.08.014</pub-id><pub-id pub-id-type="pmid">26359992</pub-id></element-citation></ref><ref id="b0275"><label>55</label><element-citation publication-type="journal" id="h0275"><person-group person-group-type="author"><name name-style="western"><surname>Carbonell</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nagano-Saito</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leyton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cisek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Benkelfat</surname><given-names>C.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Dopamine precursor depletion impairs structure and efficiency of resting state brain functional networks</article-title><source>Neuropharmacology</source><volume>84</volume><year>2014</year><fpage>90</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.12.021</pub-id><pub-id pub-id-type="pmid">24412649</pub-id></element-citation></ref><ref id="b0280"><label>56</label><element-citation publication-type="journal" id="h0280"><person-group person-group-type="author"><name name-style="western"><surname>Gilat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Ehgoetz Martens</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Georgiades</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Walton</surname><given-names>C.C.</given-names></name><etal/></person-group><article-title>Dopamine depletion impairs gait automaticity by altering cortico-striatal and cerebellar processing in Parkinson's disease</article-title><source>Neuroimage</source><volume>152</volume><year>2017</year><fpage>207</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.02.073</pub-id><pub-id pub-id-type="pmid">28263926</pub-id></element-citation></ref><ref id="b0285"><label>57</label><element-citation publication-type="journal" id="h0285"><person-group person-group-type="author"><name name-style="western"><surname>Manza</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>H.C.</given-names></name></person-group><article-title>Resting-state functional connectivity of the striatum in early-stage Parkinson's disease: cognitive decline and motor symptomatology</article-title><source>Hum Brain Mapp</source><volume>37</volume><issue>2</issue><year>2016</year><fpage>648</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1002/hbm.23056</pub-id><pub-id pub-id-type="pmid">26566885</pub-id><pub-id pub-id-type="pmcid">PMC4843498</pub-id></element-citation></ref><ref id="b0290"><label>58</label><element-citation publication-type="journal" id="h0290"><person-group person-group-type="author"><name name-style="western"><surname>Nagano-Saito</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lissemore</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Gravel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leyton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carbonell</surname><given-names>F.</given-names></name><name name-style="western"><surname>Benkelfat</surname><given-names>C.</given-names></name></person-group><article-title>Posterior dopamine D2/3 receptors and brain network functional connectivity</article-title><source>Synapse</source><volume>71</volume><issue>11</issue><year>2017</year><pub-id pub-id-type="doi">10.1002/syn.21993</pub-id><pub-id pub-id-type="pmid">28700819</pub-id></element-citation></ref><ref id="b0295"><label>59</label><element-citation publication-type="journal" id="h0295"><person-group person-group-type="author"><name name-style="western"><surname>Szewczyk-Krolikowski</surname><given-names>K.</given-names></name><name name-style="western"><surname>Menke</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Rolinski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duff</surname><given-names>E.</given-names></name><name name-style="western"><surname>Salimi-Khorshidi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Filippini</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Functional connectivity in the basal ganglia network differentiates PD patients from controls</article-title><source>Neurology</source><volume>83</volume><issue>3</issue><year>2014</year><fpage>208</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1212/wnl.0000000000000592</pub-id><pub-id pub-id-type="pmid">24920856</pub-id><pub-id pub-id-type="pmcid">PMC4117363</pub-id></element-citation></ref><ref id="b0300"><label>60</label><element-citation publication-type="journal" id="h0300"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Altered resting-state functional connectivity of the striatum in Parkinson's Disease after levodopa administration</article-title><source>PLoS One</source><volume>11</volume><issue>9</issue><year>2016</year><object-id pub-id-type="publisher-id">e0161935</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0161935</pub-id><pub-id pub-id-type="pmcid">PMC5017636</pub-id><pub-id pub-id-type="pmid">27611959</pub-id></element-citation></ref><ref id="b0305"><label>61</label><element-citation publication-type="journal" id="h0305"><person-group person-group-type="author"><name name-style="western"><surname>Nakazono</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ogata</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mitsutake</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tobimatsu</surname><given-names>S.</given-names></name></person-group><article-title>Neural mechanisms underlying the after-effects of repetitive paired-pulse TMS with &#946; tACS on the human primary motor cortex</article-title><source>Sci Rep</source><volume>15</volume><issue>1</issue><year>2025</year><fpage>7286</fpage><pub-id pub-id-type="doi">10.1038/s41598-025-92444-4</pub-id><pub-id pub-id-type="pmid">40025222</pub-id><pub-id pub-id-type="pmcid">PMC11873315</pub-id></element-citation></ref><ref id="b0310"><label>62</label><element-citation publication-type="journal" id="h0310"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez-Catasus</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Bohnen</surname><given-names>N.I.</given-names></name><name name-style="western"><surname>D'Cruz</surname><given-names>N.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>M.</given-names></name></person-group><article-title>Striatal acetylcholine-dopamine imbalance in parkinson disease: in&#160;vivo neuroimaging study with dual-tracer PET and dopaminergic PET-informed correlational tractography</article-title><source>J Nucl Med</source><volume>63</volume><issue>3</issue><year>2022</year><object-id pub-id-type="publisher-id">438&#8211;445.10.2967/jnumed.121.261939</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2967/jnumed.121.261939</pub-id><pub-id pub-id-type="pmcid">PMC8978203</pub-id><pub-id pub-id-type="pmid">34272323</pub-id></element-citation></ref><ref id="b0315"><label>63</label><element-citation publication-type="journal" id="h0315"><person-group person-group-type="author"><name name-style="western"><surname>Schirinzi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Di Lorenzo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sancesario</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Di Lazzaro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ponzo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pisani</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Amyloid-mediated cholinergic dysfunction in motor impairment related to Alzheimer&#8217;s disease</article-title><source>Journal of Alzheimer&#8217;s Disease</source><volume>64</volume><issue>2</issue><year>2018</year><fpage>525</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.3233/jad-171166</pub-id><pub-id pub-id-type="pmid">29914023</pub-id></element-citation></ref><ref id="b0320"><label>64</label><element-citation publication-type="journal" id="h0320"><person-group person-group-type="author"><name name-style="western"><surname>Pelosin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ogliastro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lagravinese</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bonassi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mirelman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hausdorff</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Attentional control of gait and falls: is cholinergic dysfunction a common substrate in the elderly and Parkinson&#8217;s disease?</article-title><source>Front Aging Neurosci</source><volume>8</volume><year>2016</year><pub-id pub-id-type="doi">10.3389/fnagi.2016.00104</pub-id><pub-id pub-id-type="pmcid">PMC4860418</pub-id><pub-id pub-id-type="pmid">27242515</pub-id></element-citation></ref><ref id="b0325"><label>65</label><element-citation publication-type="journal" id="h0325"><person-group person-group-type="author"><name name-style="western"><surname>Rochester</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yarnall</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>David</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Lord</surname><given-names>S.</given-names></name><name name-style="western"><surname>Galna</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Cholinergic dysfunction contributes to gait disturbance in early Parkinson&#8217;s disease</article-title><source>Brain</source><volume>135</volume><issue>9</issue><year>2012</year><fpage>2779</fpage><lpage>2788</lpage><pub-id pub-id-type="doi">10.1093/brain/aws207</pub-id><pub-id pub-id-type="pmid">22961550</pub-id><pub-id pub-id-type="pmcid">PMC3437031</pub-id></element-citation></ref><ref id="b0330"><label>66</label><element-citation publication-type="journal" id="h0330"><person-group person-group-type="author"><name name-style="western"><surname>Eiden</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Weihe</surname><given-names>E.</given-names></name></person-group><article-title>VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse</article-title><source>Ann N Y Acad Sci</source><volume>1216</volume><year>2011</year><fpage>86</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2010.05906.x</pub-id><pub-id pub-id-type="pmid">21272013</pub-id><pub-id pub-id-type="pmcid">PMC4183197</pub-id></element-citation></ref><ref id="b0335"><label>67</label><element-citation publication-type="journal" id="h0335"><person-group person-group-type="author"><name name-style="western"><surname>Narendran</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lopresti</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Himes</surname><given-names>M.</given-names></name><name name-style="western"><surname>May</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers</article-title><source>Am J Psychiatry</source><volume>169</volume><issue>1</issue><year>2012</year><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2011.11010126</pub-id><pub-id pub-id-type="pmid">22193525</pub-id><pub-id pub-id-type="pmcid">PMC3405490</pub-id></element-citation></ref></ref-list><sec id="s0060" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0250">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="m0005" position="float" orientation="portrait"><caption><title>Supplementary Data 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mmc1.docx" position="float" orientation="portrait"/></supplementary-material></p></sec><fn-group><fn id="s0055" fn-type="supplementary-material"><label>Appendix A</label><p id="p0245">Supplementary data to this article can be found online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.nbas.2025.100143" id="ir005">https://doi.org/10.1016/j.nbas.2025.100143</ext-link>.</p></fn></fn-group></back></article></pmc-articleset>